Astrana Health (ASTH) 10-Q 14 Nov 14 2015 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Sep. 30, 2014	Nov. 14, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q2	'
Entity Registrant Name	'Apollo Medical Holdings, Inc.	'
Entity Central Index Key	'0001083446	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'AMEH	'
Entity Common Stock, Shares Outstanding	'	48,634,549

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Mar. 31, 2014
CURRENT ASSETS	'	'
Cash and cash equivalents	$3,950,125	$6,831,478
Marketable securities	422,181	0
Restricted cash	40,000	20,000
Accounts receivable, net	3,369,780	1,508,461
Other receivable	5,382,617	0
Due from affiliates	49,377	24,041
Prepaid expenses	145,110	42,200
Total current assets	13,359,190	8,426,180
Deferred financing costs, net	324,003	366,286
Property and equipment, net	620,036	94,948
Intangible assets, net	1,206,319	59,627
Goodwill	439,694	494,700
Other assets	108,747	41,636
TOTAL ASSETS	16,057,989	9,483,377
CURRENT LIABILITIES	'	'
Accounts payable and accrued liabilities	3,792,645	1,447,040
Medical liabilities	1,642,497	552,561
Note and line of credit payable, net of discount, current portion	304,764	444,764
Holdback consideration	136,822	0
Total current liabilities	5,876,728	2,444,365
Notes payable, net of discount - non-current portion	5,343,644	5,344,565
Convertible notes payable, net of discount	1,953,587	962,978
Warrant liability	2,750,480	2,354,624
Conversion feature liability	547,784	0
Deferred tax liability	89,791	0
Total liabilities	16,562,014	11,106,532
COMMITMENTS, CONTINGENCIES AND SUBSEQUENT EVENTS (NOTES 10 AND 11)	'	'
STOCKHOLDERS' DEFICIT	'	'
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued	0	0
Common Stock, par value $0.001; 100,000,000 shares authorized, 49,134,549 shares issued and outstanding as of September 30, 2014 and March 31, 2014, respectively	49,135	49,135
Additional paid-in-capital	16,191,023	15,083,365
Accumulated other comprehensive income	33,088	0
Accumulated deficit	-16,649,019	-16,347,588
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	-375,773	-1,215,088
Non-controlling interest	-128,252	-408,067
Total	-504,025	-1,623,155
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$16,057,989	$9,483,377

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	49,134,549	49,134,549
Common Stock, shares outstanding	49,134,549	49,134,549

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenues	$11,665,294	$2,521,421	$15,759,780	$5,136,115
Costs and expenses	'	'	'	'
Cost of services	6,161,645	2,257,945	9,421,484	4,715,875
General and administrative	3,451,907	1,043,565	5,461,239	2,965,395
Depreciation and amortization	193,281	6,528	205,180	12,883
Total costs and expenses	9,806,833	3,308,038	15,087,903	7,694,153
Income (loss) from operations	1,858,461	-786,617	671,877	-2,558,038
Other (expense) income	'	'	'	'
Interest expense	-329,258	-200,562	-606,125	-362,252
Gain on change in fair value of warrant and conversion feature liabilities	152,140	0	122,135	0
Other	-58,436	6,441	-60,912	7,490
Total other expense	-235,554	-194,121	-544,902	-354,762
Income (loss) before provision for income taxes	1,622,907	-980,738	126,975	-2,912,800
Provision for income taxes	86,989	0	98,591	800
Net income (loss)	1,535,918	-980,738	28,384	-2,913,600
Net income attributable to noncontrolling interest	-159,608	0	-329,815	0
Net income (loss) attributable to Apollo Medical Holdings, Inc.	1,376,310	-980,738	-301,431	-2,913,600
Other comprehensive income (loss):	'	'	'	'
Unrealized change in value of marketable securities	14,499	0	33,088	'
Comprehensive income (loss)	$1,390,809	($980,738)	($268,343)	($2,913,600)
NET INCOME (LOSS) PER SHARE:	'	'	'	'
BASIC	$0.03	($0.03)	($0.01)	($0.08)
DILUTED	$0.03	($0.03)	($0.01)	($0.08)
WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING:	'	'	'	'
BASIC	49,134,549	36,353,413	49,134,549	37,261,375
DILUTED	54,393,442	36,353,413	49,134,549	37,261,375

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Total	Preferred Shares	Common Shares	Additional paid-in capital	Accumulated other comprehensive income	Accumulated Deficit	Stockholders' Deficit Attributable to Apollo Medical Holdings, Inc.	Non-controlling Interest
Balance at Mar. 31, 2014	($1,623,155)	$0	$49,135	$15,083,365	$0	($16,347,588)	($1,215,088)	($408,067)
Balance (in shares) at Mar. 31, 2014	'	0	49,134,549	'	'	'	'	'
Net income	28,384	0	0	0	0	-301,431	-301,431	329,815
Issuance of warrants	132,000	'	'	132,000	'	'	132,000	0
Contribution by non-controlling interest	550,000	'	'	0	0	0	0	550,000
Distribution to non-controlling interest	-600,000	'	'	0	0	0	0	-600,000
Unrealized change in value of marketable securities	33,088	0	0	0	33,088	0	33,088	0
Stock-based compensation expense	975,658	0	0	975,658	0	0	975,658	0
Balance at Sep. 30, 2014	($504,025)	$0	$49,135	$16,191,023	$33,088	($16,649,019)	($375,773)	($128,252)
Balance (in shares) at Sep. 30, 2014	'	0	49,134,549	'	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income (loss)	$28,384	($2,913,600)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation and amortization expense	205,180	12,883
Deferred income taxes	59,314	0
Stock-based compensation expense	975,658	2,121,012
Amortization of financing costs	62,283	4,298
Amortization of debt discount	177,963	116,248
Change in fair value of warrant and conversion feature liability	-122,135	0
Changes in assets and liabilities:	'	'
Accounts receivable	-993,669	323,859
Other receivable	-5,382,617	0
Due from affiliates	42,378	17,706
Prepaid expenses and advances	-14,167	15,290
Other assets	-347	-4,100
Accounts payable and accrued liabilities	2,170,739	-6,276
Medical liabilities	668,779	0
Net cash used in operating activities	-2,122,257	-312,680
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Acquisitions, net of $620,960 in cash and cash equivalents acquired	-1,947,431	-248,800
Property and equipment acquired	-15,583	-2,219
Net cash used in investing activities	-1,963,014	-251,019
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Issuance of convertible note payable	2,000,000	0
Principal payments on notes payable	-726,082	55,235
Contribution by non-controlling interest	550,000	0
Distributions to non-controlling interest shareholder	-600,000	-240,000
Proceeds from issuance of common stock	0	728,753
Debt issuance costs	-20,000	0
Net cash provided by financing activities	1,203,918	543,988
NET DECREASE IN CASH & CASH EQUIVALENTS	-2,881,353	-19,711
CASH & CASH EQUIVALENTS, BEGINNING OF PERIOD	6,831,478	1,094,973
CASH & CASH EQUIVALENTS, END OF PERIOD	3,950,125	1,075,262
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION	'	'
Interest paid	356,196	169,802
Income taxes paid	18,588	38,356
Non-Cash Financing Activities:	'	'
Acquisition related holdback liability consideration	136,822	0
Convertible note warrant	487,620	13,316
Convertible note conversion feature	578,155	125,000
Acquisition related warrant consideration	$132,000	$101,817

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	6 Months Ended
	Sep. 30, 2014
Acquisitions, net of cash acquired	$620,960

Description_of_Business

Description of Business	6 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Description of Business	'
	1.            Description of Business
	Apollo Medical Holdings, Inc. (the “Company” or “ApolloMed”) and its affiliated physician groups are a physician-centric, integrated healthcare delivery system serving Medicare, Commercial and Medi-Cal beneficiaries in California.  ApolloMed’s physician network consists of hospitalists, primary care physicians and specialist physicians primarily through the Company’s owned and affiliated physician groups. ApolloMed operates as a medical management holding company through the following subsidiary management companies: Apollo Medical Management, Inc. (“AMM”), Pulmonary Critical Care Management, Inc. (“PCCM”), Verdugo Medical Management, Inc. (“VMM”), and ApolloMed ACO, Inc. (“ApolloMed ACO). Through AMM, PCCM, and VMM, the Company manages affiliated medical groups, which consist of ApolloMed Hospitalists (“AMH"), ApolloMed Care Clinic (“ACC”), Maverick Medical Group, Inc. (“MMG”), Los Angeles Lung Center (“LALC”), Eli Hendel, M.D., Inc. (“Hendel”), AKM Medical Group, Inc. (“AKM”) (see Note 3), and Southern California Heart Centers (“SCHC”) (see Note 3); and a controlling interest in ApolloMed Palliative Services, LLC (“APS”). AMM, PCCM and VMM each operate as a physician practice management company (“PPM”) and are in the business of providing management services to physician practice corporations (“PPC”) under long-term management service agreements. ApolloMed ACO participates in the Medicare Shared Savings Program (“MSSP”), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers.
	Change in Fiscal Year
	On May 16, 2014, the board of directors of the Company approved a change to the Company's fiscal year end from January 31 to March 31. The March 31, 2014 amounts included in the accompanying condensed consolidated financial statements and related notes thereto are unaudited.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2.        Summary of Significant Accounting Policies
	Accounting Principles
	These condensed consolidated statements reflect all adjustments, consisting of normal recurring adjustments, which, in management’s opinion, are necessary, and should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2014 as filed with the Securities and Exchange Commission (“SEC”) on May 8, 2014.
	Principles of Consolidation
	The Company’s consolidated financial statements include the accounts of (1) Apollo Medical Holdings, Inc. and its wholly owned subsidiaries AMM, PCCM, and VMM, (2) the Company’s controlling interest in ApolloMed ACO, and APS, which is a newly formed entity with no operations to date to provide home health and hospice medical services and in which a non-controlling interest in APS contributed $550,000 in cash; and (3) PPCs managed under long-term management service agreements including AMH, MMG, ACC, LALC, Hendel, AKM and SCHC. Some states have laws that prohibit business entities, such as ApolloMed, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the corporate practice of medicine), or engaging in certain arrangements with physicians, such as fee-splitting. In California, the Company operates by maintaining long-term management service agreements with the PPCs, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide hospitalist services. Under the management agreements, the Company provides and performs all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. Each management agreement typically has a term from 10 to 20 years unless terminated by either party for cause. The management agreements are not terminable by the PPCs, except in the case of material breach or bankruptcy of the respective PPM.
	Through the management agreements and the Company’s relationship with the stockholders of the PPCs, the Company has exclusive authority over all non-medical decision making related to the ongoing business operations of the PPCs. Consequently, the Company consolidates the revenue and expenses of each PPC from the date of execution of the applicable management agreement.
	All intercompany balances and transactions have been eliminated in consolidation.
	Revenue Recognition
	Revenue consists of contracted, fee-for-service, and capitation revenue. Revenue is recorded in the period in which services are rendered. Revenue is principally derived from the provision of healthcare staffing services to patients within healthcare facilities. The form of billing and related risk of collection for such services may vary by customer. The following is a summary of the principal forms of the Company’s billing arrangements and how net revenue is recognized for each.
	Contracted revenue
	Contracted revenue represents revenue generated under contracts for which the Company provides physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates. Revenue in such cases is recognized as the hours are worked by the Company’s staff and contractors. Additionally, contract revenue also includes supplemental revenue from hospitals where the Company may have a fee-for-service contract arrangement or provide physician advisory services to the medical staff at a specific facility. Contract revenue for the supplemental billing in such cases is recognized based on the terms of each individual contract. Such contract terms generally either provides for a fixed monthly dollar amount or a variable amount based upon measurable monthly activity, such as hours staffed, patient visits or collections per visit compared to a minimum activity threshold. Such supplemental revenues based on variable arrangements are usually contractually fixed on a monthly, quarterly or annual calculation basis considering the variable factors negotiated in each such arrangement. Such supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement. Additionally, the Company derives a portion of the Company’s revenue as a contractual bonus from collections received by the Company’s partners and such revenue is contingent upon the collection of third-party billings. These revenues are not considered earned and therefore not recognized as revenue until actual cash collections are achieved in accordance with the contractual arrangements for such services.
	Fee-for-service revenue
	Fee-for-service revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company’s contracted and employed physicians. Under the fee-for-service arrangements, the Company bills patients for services provided and receives payment from patients or their third-party payers. Fee-for-service revenue is reported net of contractual allowances and policy discounts. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. Fee-for-service revenue is recognized in the period in which the services are rendered to specific patients and reduced immediately for the estimated impact of contractual allowances in the case of those patients having third-party payor coverage. The recognition of net revenue (gross charges less contractual allowances) from such visits is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company’s billing systems as well as an estimate of the revenue associated with medical services.
	Capitation revenue
	Capitation revenue (net of capitation withheld to fund risk share deficits) is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted health maintenance organizations (each, an “HMO”) finalizing of monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a provider service agreement (PSA) or capitated arrangements directly made with various managed care providers including HMO’s. Capitation revenue under the PSA and HMO contracts is prepaid monthly to the Company based on the number of enrollees electing the Company as their healthcare provider. Additionally, Medicare pays capitation using a “Risk Adjustment model,” which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on an interim basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.
	HMO contracts also include provisions to share in the risk for enrollee hospitalization, whereby the Company can earn additional incentive revenue or incur penalties based upon the utilization of hospital services. Typically, any shared risk deficits are not payable until and unless the Company generates future risk sharing surpluses, or if the HMO withholds a portion of the capitation revenue to fund any risk share deficits. At the termination of the HMO contract, any accumulated risk share deficit is typically extinguished. Due to the lack of access to information necessary to estimate the related costs, shared-risk amounts receivable from the HMOs are only recorded when such amounts are known. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following fiscal year.
	In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. These incentives, which are included in other revenues, are generally recorded in the third and fourth quarters of the fiscal year and are recorded when such amounts are known.
	Under full risk capitation contracts, an affiliated hospital entered into agreements with several HMOs, pursuant to which, the affiliated hospital will provide hospital, medical, and other healthcare services to enrollees under a fixed capitation arrangement ("Capitation Arrangement"). Under the risk pool sharing agreement, the affiliated hospital and medical group agreed to establish a Hospital Control Program to serve the enrollees, pursuant to which, the medical group is allocated a 90% residual interest in the profit or loss, after deductions for costs to affiliated hospitals. The Company participates in the full risk programs under the terms of the PSA, whereby the Company is wholly liable for the deficits allocated to the medical group under the arrangement. The related liability is included in medical liabilities in the accompanying unaudited condensed consolidated balance sheets at September 30 and March 31, 2014 (see "Medical Liabilities" in this Note 2, below).
	Medicare Shared Savings Program Revenue
	The Company through its subsidiary, ApolloMed ACO, participates in the MSSP sponsored by the Centers for Medicare & Medicaid Services (“CMS”). The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated by the ACO participant relative to the ACO participants trailing 24 month medical service history. The MSSP is a newly formed program with minimal history of payments to ACO participants. The Company considers revenue, if any, under the MSSP, as contingent upon the realization of program savings as determined by CMS, and are not considered earned and therefore are not recognized as revenue until notice from CMS that cash payments are to be imminently received.
	During the second quarter of 2014, CMS announced that ApolloMed ACO generated $10.98 million in program savings from cost savings created in connection with rendering medical services to Medicare patients in 2012. In connection with these cost savings, the Company earned $5.38 million which has been reported in the line items “Net Revenue and “other receivable” in the September 30, 2014 condensed consolidated financial statements. Revenue from the MSSP is determined and awarded annually, and the Company does not anticipate additional revenue in fiscal 2015. Future ACO program savings for services performed in calendar year 2013 and 2014 are not estimable.
	Concentrations
	Excluding the MSSP related revenue, the Company had no major payors during the three months ended September 30, 2014 which contributed more than 10% of net revenues, and had three major payors during the three months ended September 30, 2013 which contributed 16.1%, 16.1% and 16.8% of net revenues, respectively. During the six months ended September 30, 2014, excluding the MSSP related revenue, the Company had no major payors which contributed more than 10% of net revenues and had three major payors during the six months ended September 30, 2013 which contributed 15.8%, 16.1% and 17.6% of net revenues, respectively.
	The Company had one major payor that accounted for 12.5 % of accounts receivable as of September 30, 2014, and two major payors that accounted for 21.7% and 9.6% of accounts receivable, respectively, as of March 31, 2014.
	Cash Equivalents and Marketable Securities
	The Company’s cash equivalents consist of bank demand deposits and highly liquid investments with original maturities of three months or less from the original purchase date.
	The Company’s marketable securities consist of our holdings in equity securities and mutual funds. These are classified as available-for-sale, which are measured each reporting period at fair value, with any unrealized change in value reflected in other comprehensive income or loss, and realized gains or losses in the statement of operations in the accompany condensed consolidated statements of operations and comprehensive income (loss). Other than temporary impairments are evaluated for securities that have been in a continuous unrealized loss position longer than one year.
	The following is a summary of cash equivalents and marketable securities:
	As of September 30, 2014			Gross		Gross		Estimated		Cash and		Marketable
				Unrealized		Unrealized		Fair		Cash		Securities
		Cost		Gain		Loss		Value		Equivalents		(all current)
	Bank demand deposits	$	3,856,285	$	-	$	-	$	3,856,285	$	3,856,285	$	-
	Money market funds		93,840		-		-		93,840		93,840		-
	Mutual funds		148,028		966		-		148,994		-		148,994
	Equity securities		241,065		32,122		-		273,187		-		273,187
		$	4,339,218	$	33,088	$	-	$	4,372,306	$	3,950,125	$	422,181
	As of March 31, 2014			Gross		Gross		Estimated		Cash and
				Unrealized		Unrealized		Fair		Cash
		Cost		Gain		Loss		Value		Equivalents
	Bank demand deposits	$	6,831,478		-		-	$	6,831,478	$	6,831,478
		$	6,831,478	$	-	$	-	$	6,831,478	$	6,831,478
	Medical Liabilities
	The Company is responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees under risk-pool arrangements. The Company provides integrated care to health plan enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements, company-operated clinics and staff physicians. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services in the accompanying condensed consolidated statements of operations and comprehensive loss. Costs for operating medical clinics, including the salaries of medical and non-medical personnel and support costs, are also recorded in cost of services.
	An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying condensed consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates of incurred but not reported claims (“IBNR”). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. The Company has a $20,000 per member professional stop-loss, none on institutional risk pools. Any adjustments to reserves are reflected in current operations.
	The Company’s IBNR reserve for the six months ended September 30, 2014 was as follows:
	Balance, beginning of period	$	274,000
	Incurred health care costs:
	Current year		1,566,856
	Prior years		-
	Total incurred health care costs		1,566,856
	Acquired medical liabilities (see Note 3 )		292,309
	Claims paid:
	Current year		-997,390
	Prior years		-64,482
	Total claims paid		-1,061,872
	Adjustments		-197,938
	Balance, end of period	$	873,355
	The Company’s accrual for its risk-pool liability for the six months ended September 30, 2014 was as follows:
	Balance, beginning of period	$	278,561
	Acquired medical liabilities (see Note 3)		128,848
	Claims paid:		-
	Accrual for net deficit from full risk capitation contracts		361,733
	Balance, end of period	$	769,142
The Company’s total medical liability at September 30, 2014 and March 31, 2014 was $1,642,497 and $552,561, respectively.
Fair Value of Financial Instruments
The Company’s accounting for Fair Value Measurement and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The hierarchy consists of three levels:
Level one — Quoted market prices in active markets for identical assets or liabilities;
Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.
The fair values of the Company’s financial instruments are measured on a recurring basis. The carrying amount reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates fair value because of the short-term maturity of those instruments. The carrying amount for borrowings under the NNA Term Loan and the Convertible Notes approximates fair value which is determined by using interest rates that are available for similar debt obligations with similar terms at the balance sheet date.
Warrant liability
The fair value of the warrant liability issued in connection with 2014 NNA Financing at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.5 years, risk free rate of 2.1%, no dividends, volatility of 72.2%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing. The fair value of the warrant liability at March 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 50% probability of down-round financing.
The fair value of the warrant liability of $487,620 related to 1,000,000 common shares issuable in connection with NNA 8% Convertible Note at issuance date of July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.7 years, risk free rate of 2.1%, no dividends, volatility of 71.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing.
Holdback liability
The holdback liability (see Note 3) fair value was determined based on the probability adjusted cash consideration, discounted at the Company's cost of debt.
Conversion feature liability
The fair value of the conversion feature liability issued in connection with 2014 NNA Financing 8% Convertible Note at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 4.5 years, risk free rate of 1.6%, no dividends, volatility of 55.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability that the Company will participate in a “down-round” financing at price per share lower than the initial NNA Financing 8% Convertible Note conversion price of $1.00 per share.
The carrying amounts and fair values of the Company's financial instruments are presented below as of:
September 30, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market currency funds	$	-	$	93,840	$	-	$	93,840
Mutual funds		-		148,994		-		148,994
Equity securities		273,187		-		-		273,187
	$	273,187	$	242,834	$	-	$	516,021
Liabilities:
Warranty liability	$	-	$	-	$	2,750,480	$	2,750,480
Holdback consideration		-		-		136,822		136,822
Conversion feature liability		-		-		547,784		547,784
	$	-	$	-	$	3,435,086	$	3,435,086
March 31, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Liabilities:
Warrant liability	$	-	$	-	$	2,354,624	$	2,354,624
	$	-	$	-	$	2,354,624	$	2,354,624
The following summarizes the activity of Level 3 inputs measured on a recurring basis for the three and six months ended September 30, 2014:
	Three months			Six months
Balance, beginning of period	$	2,521,451	$	2,354,624
Warrant liability incurred (Note 7)		487,620		487,620
Change in warrant liability		-121,769		-91,764
Holdback consideration		-		136,822
Conversion feature liability incurred (Note 7)		578,155		578,155
Change in conversion feature liability		-30,371		-30,371
Balance, end of period	$	3,435,086	$	3,435,086
The unrealized gain on changes in fair value of warrant and conversion feature liability is included in the accompanying condensed consolidated statement of operations and comprehensive loss.
Non-controlling Interest
The non-controlling interest recorded in the Company’s condensed consolidated financial statements represents the pre-acquisition equity of those PPC’s in which the Company has determined that it has a controlling financial interest and for which consolidation is required as a result of management contracts entered into with these entities. The nature of these contracts provide the Company with a monthly management fee to provide the services described above, and as such, the adjustments to non-controlling interests in any period subsequent to initial consolidation would relate to either capital contributions or distributions by the non-controlling parties as well as income or losses attributable to certain non-controlling interests.
Basic and Diluted Earnings per Share
Basic net income (loss) per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted net income (loss) per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for secured convertible notes, and the treasury stock method for options and warrants.
The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would be anti-dilutive:
		Three Months Ended September 30,				Six Months Ended September 30,
		2014		2013		2014		2013
Options		-		4,373,687		3,657,216		4,547,125
Warrants		-		1,428,067		1,495,803		1,535,402
9% Convertible Notes		799,523		674,528		748,824		785,714
		799,523		6,476,282		5,901,843		6,868,241
New Accounting Standards
In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40). The guidance in this ASU requires disclosure of uncertainties about an entity’s ability to continue as a going concern even if an entity’s liquidation is not imminent. There may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting and this guidance should be followed to determine whether to disclose information about the relevant conditions and events. This guidance is effective for the Company on December 31, 2016 and the adoption of this standard is not expected to have a significant impact on its condensed consolidated financial statements or notes thereto.
Use of Estimates
The preparation of financial statements in conformity with United States GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may materially differ from these estimates under different assumptions or conditions.
Reclassifications
Certain reclassifications have been made to the accompanying March 31, 2014 condensed consolidated financial statements to conform them to the September 30, 2014 presentation.

Acquisitions

Acquisitions	6 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisition	'
	3.  Acquisitions
	SCHC
	On July 22, 2014, pursuant to a Stock Purchase Agreement dated as of July 21, 2014 (the “Purchase Agreement”) among the Southern California Heart Centers, a Medical Corporation, a medical group that provides professional medical services in Los Angeles County, California (“SCHC”), the shareholders of SCHC (the “Sellers”) and a Company affiliate, SCHC Acquisition, A Medical Corporation (the “Affiliate”), solely owned by Dr. Warren Hosseinion as physician shareholder and the Chief Executive Officer of the Company, the Affiliate acquired all of the outstanding shares of capital stock of SCHC from the Sellers. The purchase price for the shares was (i) $2,000,000 in cash, (ii) $428,391 to pay off and discharge certain indebtedness of SCHC (iii) warrants to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share and (iv) a contingent amount of up to $1,000,000 payable, if at all, in cash. The acquisition was funded by an intercompany loan from AMM, which also provided an indemnity in favor of one of the Sellers relating to certain indebtedness of SCHC that remained outstanding following the closing of the acquisition. Following the acquisition of SCHC, the Affiliate was merged with and into SCHC, with SCHC being the surviving corporation. The indebtedness of SCHC was paid off following the acquisition and did not remain outstanding as of September 30, 2014.
	In connection with the acquisition of SCHC, AMM entered into a management services agreement with the Affiliate on July 21, 2014. As a result of the Affiliate’s merger with and into SCHC, SCHC is now the counterparty to this management services agreement and bound by its terms. Pursuant to the management services agreement, AMM will manage all non-medical services for SCHC, will have exclusive authority over all non-medical decision making related to the ongoing business operations of SCHC, and is the primary beneficiary of SCHC, and the financial statements of SCHC will be consolidated as a variable interest entity with those of the Company from July 21, 2014.
	The Company accounted for the acquisition as a business combination using the acquisition method of accounting which requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. The acquisition-date fair value of the consideration transferred was as follows:
	Cash consideration	$	2,428,391
	Fair value of warrant consideration		132,000
		$	2,560,391
	The warrants were classified as equity. The fair value of the warrants was determined using the Black-Scholes option pricing model using the following inputs: share price of $0.54 (adjusted for a lack of control discount), exercise price of $1.00, expected term of 4 years, volatility of 54% and a risk free interest rate of 1.35%.
	A contingent payment obligation of $1,000,000 was considered a post-combination transaction and therefore it will be recorded as post-combination compensation expense over the term of the arrangement and not as purchase consideration. The compensation expense will be accrued in each reporting period using the total probability weighted payment of $827,000, allocated to each quarter, and between each Seller, pro rata over the term of the arrangement according to the relative weight of the payment milestones. The remaining liability will be re-measured at every reporting period date, with any adjustment reflected prospectively in compensation expense.
	Transaction costs are not included as a component of consideration transferred and were expensed as incurred. The related transaction costs expensed for the three and six months ended September 30, 2014 were approximately $124,000 in each period and are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive income (loss).
	Under the acquisition method of accounting, the total purchase price was allocated to the underlying tangible and intangible assets acquired and liabilities assumed based on their respective fair values, with the remainder allocated to goodwill. The preliminary allocation of the total purchase price to the net assets acquired and liabilities assumed and included in the Company’s condensed consolidated balance sheet at September 30, 2014 is as follows:
	Cash and cash equivalents	$	264,601
	Accounts receivable		840,433
	Receivable from affiliate		67,714
	Prepaid expenses and other current assets		82,430
	Property and equipment		584,377
	Identifiable intangible assets		1,121,000
	Goodwill		161,559
	Other assets		66,762
	Total assets acquired		3,188,876
	Accounts payable and accrued liabilities		134,427
	Note payable to financial institution		463,582
	Deferred tax liability		30,477
	Total liabilities assumed		628,485
	Net assets acquired	$	2,560,391
	The intangible assets acquired consisted of the following:
		Life		Additions
		(yrs)
	Network relationships	5		$	910,000
	Trade name	5			110,000
	Non-compete agreements	3			101,000
				$	1,121,000
	The network relationships were valued using the multi-period excess earnings method based on projected revenue and earnings over a 5 year period. The trade name was computed using the relief from royalty method, assuming a 1% royalty rate, and the non-compete agreements were valued using a with-and-without method.
	See below for the combined SCHC and AKM pro forma results of operations.
	AKM
	In May 2014, AMM entered into a management services agreement with AKM Acquisition Corp, Inc. (“AKMA”), a newly-formed provider of physician services and an affiliate of the Company owned by Dr. Warren Hosseinion as a physician shareholder, to manage all non-medical services for AKMA. AMM has exclusive authority over all non-medical decision making related to the ongoing business operations of AKMA and is the primary beneficiary; consequently, AMM consolidated the revenue and expenses of AKMA from the date of execution of the management services agreements. On May 30, 2014 (the “Closing Date”) AKMA entered into a stock purchase agreement (the “AKM Purchase Agreement”) with the shareholders of AKM Medical Group, Inc.(“AKM”), a Los Angeles, CA-based independent practice association (“IPA”).  Immediately following the closing, AKMA merged with and into AKM, with AKM being the surviving entity and assuming the rights and obligations under the management services agreement. Under the AKM Purchase Agreement all of the issued and outstanding shares of capital stock of AKM was acquired for approximately $280,000, of which $140,000 was paid at closing and $136,822 (the “Holdback Liability”) is payable subject to the outcome of incurred but not reported risk-pool claims and other contingent claims that existed at the acquisition date. The acquisition allows the Company to execute on its strategy to provide high-quality, cost-efficient healthcare delivery through integrated services and network offerings.
	The Company accounted for the acquisition as a business combination using the acquisition method of accounting which requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates.  The acquisition-date fair value of the consideration transferred was as follows:
	Cash consideration	$	140,000
	Fair value of holdback consideration due to seller		136,822
	Total purchase consideration	$	276,822
	Under the acquisition method of accounting, the total purchase price was allocated to AKM’s net tangible assets based on their estimated fair values as of the closing date. The preliminary allocation of the total purchase price to the net assets acquired and included in the Company’s condensed consolidated balance sheet is as follows:
	Cash and cash equivalents	$	356,359
	Marketable securities		389,094
	Accounts receivable		27,217
	Prepaid expenses and other assets		26,311
	Intangibles		156,000
	Goodwill		-216,563
	Accounts payable and accrued liabilities		-40,439
	Medical payables		-421,157
	Net assets acquired	$	276,822
	Before recognizing a gain from a bargain purchase, the Company is required to reassess its identification of assets acquired and liabilities assumed to validate that all assets and liabilities that the acquirer is able to identify at the acquisition date are properly recognized. The guidance in ASC 805 requires that this additional reassessment be performed to verify that the identification and measurement of all components of the business combination were consistent with the requirements of ASC 805. Accordingly, as the purchase price allocation is preliminary and subject to reassessment, the Company will classify the goodwill bargain purchase as a contra to goodwill until it has completed its review of the procedures used to measure the included amounts, which is expected to be during the quarter ending December 31, 2014.
	Under the AKM Purchase Agreement, former shareholders of AKM are entitled to be paid the Holdback Amount of up to approximately $140,000 within 6 months of the Closing Date. No later than 30 days after the six month period, AKM will prepare a closing statement which will state the actual cash position (as defined) (“Actual Cash Position”) of AKM. If the actual cash position of AKM is less than $461,104 (the “Target Amount”), the former shareholders of AKM will pay the difference between the Target Amount and the Actual Cash Position, which will be deducted from the Holdback Amount, but in no case will exceed the amount previously paid to the former shareholders of AKM in connection with the transaction. If the Actual Cash Position exceeds the Target Amount, then that difference will be added to the Holdback Amount. Any indemnification payment made by the former shareholders of AKM will also be paid from the Holdback Amount; if the Holdback Amount is insufficient, the former shareholders of AKM are liable for paying the balance, which cannot exceed amounts previously paid to the former shareholders of AKM under the AKM Purchase Agreement. The Company determined the preliminary fair value was determined based on the cash consideration discounted at the Company's cost of debt.
	Transaction costs are not included as a component of consideration transferred and were expensed as incurred. The related transaction costs expensed for the three and six months ended September 30, 2014 were approximately $0 and $37,000, respectively.
	Pro Forma Financial Information
	The results of operations for AKM and SCHC are included in the condensed consolidated statements of operations from the acquisition date of each. The pro forma results of operations are prepared for comparative purposes only and do not necessarily reflect the results that would have occurred had the acquisitions occurred at the beginning of the years presented or the results which may occur in the future. The following unaudited pro forma results of operations for the three and six months ended September 30, 2014 assume both the AKM and SCHC acquisitions had occurred on April 1, 2014, and for the six months ended September 30, 2013 assume the acquisitions had occurred on April 1, 2013:
		Three months ended September 30,					Six months ended September 30,
		2014			2013		2014		2013
		(unaudited)			(unaudited)		(unaudited)		(unaudited)
	Net revenue	$	11,899,142		$	4,477,640	$	17,956,326	$	9,135,956
	Net income (loss)	$	1,410,936		$	-1,067,658	$	-209,441	$	-3,054,008
	Basic income (loss) per share	$	0.03		$	-0.02	$	0	$	-0.08
	Diluted income (loss) per share	$	0.03		$	-0.02	$	0	$	-0.08
From the applicable closing date to September 30, 2014, revenues and net loss related to AKM and SCHC included the accompanying condensed and consolidated statement of operations were $1,872,529 and $(260,624), respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	6 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	4. Goodwill and Other Intangible Assets
	Goodwill
	The following is a summary of goodwill activity for the six months ended September 30, 2014:
	Balance, beginning of period		$	494,700
	Acquisition of AKM			-216,565
	Acquisition of SCHC			161,559
	Balance, end of period		$	439,694
	Other Intangible Assets
	Other intangible assets consisted of the following:
		Weighted-average life		Balance at		Additions		Balance at
		(Yrs)		31-Mar-14				30-Sep-14
	Intangible assets:
	Exclusivity	4		$	40,000	$	-	$	40,000
	Non-compete	4			28,400		120,000		148,400
	Payor relationships	5			-		94,000		94,000
	Network relationships	5			-		910,000		910,000
	Trade name	5			-		153,000		153,000
	Totals				68,400		1,277,000		1,345,400
	Accumulated amortization				-8,773		-130,308		-139,081
	Total other intangibles, net			$	59,627	$	1,146,692	$	1,206,319
	The amortization expense for the three and six months ended September 30, 2014 was approximately $125,000 and $130,000, respectively. The amortization expense for the three and six months ended September 30, 2013 was approximately $1,000 in each period.
	Future amortization expense is estimated to be as follows for the period from October 1, 2014 to March 31, 2015 and for each for the five years ending March 31 thereafter:
	October 1, 2014 to March 31, 2015	$	255,000
	2016	$	326,000
	2017	$	259,000
	2018	$	192,000
	2019	$	125,000
	Thereafter	$	46,000

Accounts_Payable_and_Accrued_L

Accounts Payable and Accrued Liabilities	6 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities	'
	5. Accounts Payable and Accrued Liabilities
	Accounts payable and accrued liabilities consisted of the following:
		September 30,		March 31,
		2014		2014
	Accounts payable	$	1,456,796	$	824,334
	Physician share of MSSP ACO savings		1,400,000		-
	Accrued compensation		809,772		546,078
	Income taxes payable		85,477		4,149
	Accrued interest		28,049		19,780
	Accrued professional fees		12,550		52,699
		$	3,792,645	$	1,447,040

Notes_and_Lines_of_Credit_Paya

Notes and Lines of Credit Payable	6 Months Ended
	Sep. 30, 2014
Notes Payable [Abstract]	'
Notes and Lines of Credit Payable	'
	6. Notes and Line of Credit Payable
	Notes and line of credit payable consist of the following:
		September 30,		March 31,
		2014		2014
	Term loan payable to NNA due March 28, 2019, net of debt discount of $1,183,856 (September 30, 2014) and $1,305,435 (March 31, 2014)	$	5,553,644	$	5,694,565
	Unsecured revolving line of credit due to financial institution due June 5, 2015		94,764		94,764
		$	5,648,408	$	5,789,329
	Senior Secured Note
	The Company entered into a Senior Secured Note (“Note”) agreement on February 1, 2012 with SpaGus Capital Partners, LLC (“SpaGus”) an entity in which Gary Augusta, a director and shareholder of the Company, holds an ownership interest.
	On September 15, 2012, SpaGus agreed to allow the Company to defer payment of the scheduled principal payments due on September 15 and October 15, 2012, and amended the Note effective October 15, 2012 in which SpaGus agreed to provide additional principal to the Company in the amount of $230,000. The terms of the amended Note in the amount of $500,000 provided for borrowings to bear interest at 8.0 % per annum with accrued interest payable in arrears on each of December 28, 2012, March 31, 2013, June 30, 2013, and October 15, 2013. The amended Note matured and was repaid, including accrued unpaid interest, on October 16, 2013.
	Medical Clinic Acquisition Promissory Notes
	In connection with the September 1, 2013 acquisition of a Los Angeles, CA medical clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in ten installments of $15,000 per month commencing December 1, 2013.  The Company determined the fair value of the note using an interest rate of 5.45% per annum to discount future cash flows, which was based on Moody’s Baa-rated corporate bonds at the valuation date.  The note was secured by substantially all assets of the clinic.
	In connection with the January 6, 2014 acquisition of Fletcher Medical Clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in installments of $15,000 per month for five months commencing April 1, 2014 under a non-interest bearing promissory note. The Company determined the fair value of the note using an interest rate of 5.30% per annum to discount future cash flows, which was based on Moody’s Baa-rated corporate bonds at the valuation date. The note was secured by substantially all assets of the acquired clinic.
	In connection with the December 7, 2013 acquisition of Eagle Rock Medical Clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in installments of $10,000 per month for eight months commencing March 1, 2014 under a non-interest bearing promissory. The Company determined the fair value of the note using an interest rate of 5.46 % per annum to discount future cash flows, which was based on based on index of Moody's Baa-rated corporate bonds at of the valuation date. The note was secured by substantially all assets of the acquired clinic.
	The medical clinic acquisition promissory notes described above were repaid in connection with the equity and debt financing with NNA of Nevada, Inc. that closed on March 28, 2014 (see 2014 NNA Financing below).
	NNA Credit Agreements
	On October 15, 2013, the Company entered into a $2.0 million secured revolving credit facility (the “Revolving Credit Agreement”) with NNA of Nevada, Inc., (“the Lender” or “NNA”). On December 20, 2013 the Company entered into the First Amendment to the Credit Agreement (the “Amended Credit Agreement”), which increased the revolving credit facility from $2 million to $4 million.   The proceeds of the Amended Credit Agreement were used by the Company to repay the $500,000 Note to SpaGus Apollo, LLC, and were used to pay or repay certain of the Company’s 10% Notes (see Note 7), to refinance certain other indebtedness of the Company, and for working capital and for general corporate purposes. The Amended Credit Agreement was refinanced on March 28, 2014 in connection with 2014 NNA Financing.
	2014 NNA Financing
	On March 28, 2014, the Company entered into certain credit and investment agreements with NNA (the “2014 NNA Financing”) which provided for a $7.0 million secured term loan (“Term Loan”), a $1.0 million secured line of credit (“Revolving Loan”), and a $2.0 million convertible note commitment (“Convertible Note”). In addition, NNA acquired 2,000,000 shares of the Company’s common stock, warrants to acquire the Company’s common stock, and certain registration rights (see Note 9). The Term Loan and Revolving Loan are secured by substantially all assets of the Company, and are guaranteed by the Company’s subsidiaries and certain of its consolidated medical corporations.
	The Company determined the fair value of the proceeds of $9.0 million in part based on the following inputs for the warrant liability: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share and a 50% probability of down-round financing. The common stock issuance was recorded at $899,739 (a discount of $1,100,261 to the face amount), the Term Loan was recorded at $5,745,637 (a discount of $1,254,363 to the face amount), and a corresponding warrant liability of $2,354,624 was recorded.
	The Term Loan accrues interest at a rate of 8.0% per annum. A portion of the principal amount of the Term Loan is repaid on the last business day of each calendar quarter, which provides for quarterly payments of $87,500 in the first year, $122,500 in the second year, $122,500 in the third year, $175,000 in the fourth year, and $210,000 in the fifth year. The Term Loan reflected an original issue discount of $1,305,435 associated with the issuance of 3 million warrants to acquire the Company’s common stock (see Note 9) and payment of a fee to NNA of $80,000 of which $51,072 was considered a debt discount, $7,998 was recorded to equity, and $20,930 allocated to warrant liability was immediately recorded as interest expense. The discount will be amortized to interest expense over the expected term of the loan using the effective interest method.
	The Revolving Loan will bear interest at the rate of three month LIBOR plus 6.0% per annum. No amounts were borrowed under the Revolving Loan at September 30, 2014. The Term Loan and Revolving Loan mature on March 28, 2019.
	The NNA 8% Convertible Note commitment provided for a convertible note commitment of $2,000,000, which, on July 31, 2014, the Company fully exercised (see Note 7).
	The Company incurred $235,119 in third party costs related to the 2014 NNA Financing, which were allocated to the related debt and equity instruments based on their relative fair values, of which $150,101 was classified as deferred financing costs which will be deferred and amortized over the life of the loan using the effective interest method.
	The 2014 NNA Financing credit agreement and the Convertible Note provide for certain financial covenants which financial covenants the Company was in compliance with as of and for the six-month period ended September 30, 2014.
	In addition, the 2014 NNA Financing credit agreement and the Convertible Note include: (1) certain negative covenants that, subject to exceptions, limit the Company’s ability to, among other things incur additional indebtedness, engage in future mergers, consolidations, liquidations and dissolutions, sell assets, pay dividends and distributions on or repurchase capital stock, and enter into or amend other material agreements; and (2) certain customary representations and warranties, affirmative covenants and events of default, which are set forth in more detail in the 2014 NNA Financing credit agreement and Convertible Note.
	Unsecured revolving line of credit
	Included in “Note and line of credit payable” in the accompanying condensed consolidated balance sheet is a $100,000 revolving line of credit with a financial institution of which $94,764 was outstanding at September 30, 2014 and March 31, 2014. Borrowings under the line of credit bear interest at the prime rate (as defined) plus 4.50% (7.75% per annum at March 31, 2014 and September 30, 2014), interest only is payable monthly, and the line of credit matures June 5, 2015. The line of credit is unsecured.
	Interest expense associated with the notes and lines of credit payable consisted of the following:
		Three months ended				Six months ended
		September 30,				September 30,
		2014		2013		2014		2013
	Interest expense	$	143,845	$	25,089	$	287,998	$	56,087
	Amortization of loan fees and discount		71,673		35,061		142,924		39,780
		$	215,518	$	60,151	$	430,922	$	95,868

Convertible_Notes_Payable

Convertible Notes Payable	6 Months Ended
	Sep. 30, 2014
Convertible Notes [Abstract]	'
Convertible Notes Payable	'
	7.  Convertible Notes Payable
	Convertible notes payable consist of the following:
		September		March
		30,		31,
		2014		2014
	9% Senior Subordinated Convertible Notes due February 15, 2016, net of debt discount of $99,973 (September 30, 2014) and $137,393 (March 31, 2014)	$	1,000,398	$	962,978
	8% Senior Subordinated Convertible Note Payable to NNA due March 28, 2019, net of debt discount of $1,046,811		953,189		-
		$	1,953,587	$	962,978
	10% Senior Subordinated Callable Convertible Notes
	On October 16, 2009, the Company issued $1,250,000 of 10% Senior Subordinated Callable Convertible Notes (the “10% Notes”). The 10% Notes were sold through a placement agent in the form of Units. Each Unit comprised one 10% Senior Subordinated Callable Convertible Note with a par value $25,000, and warrants to purchase shares of the Company’s common stock.
	On December 20, 2013, the Company redeemed the 10% Notes for cash and/or conversion into shares of the Company’s Common Stock.
	8% Senior Subordinated Convertible Promissory Notes due February 1, 2015
	On or about February 21, 2013, the Company entered into a Settlement Agreement and Release (collectively, the “Settlement Agreements”) with each of the holders of 8% Notes (each, an “8% Holder” and, collectively, the “8% Holders”). Under the Settlement Agreements, the Company agreed to redeem for cash and/or convert into shares of the Company’s common stock the 8% Notes of the 8% Holders. In February 2014 the Company redeemed and converted $150,000 in original principal amount plus accrued interest thereon, for total cash payments of approximately $106,000 and issuance of approximately182,000 shares of the Company’s common stock.
	9% Senior Subordinated Callable Convertible Promissory Notes due February 15, 2016
	The 9% Notes bear interest at a rate of 9% per annum, payable semi-annually on August 15 and February 15, and mature February 15, 2016, and are subordinated. The principal of the 9% Notes plus any accrued yet unpaid interest is convertible at any time by the holder at a conversion price of $0.40 per share of Common Stock, subject to adjustment for stock splits, stock dividends and reverse stock splits. After 60 days prior notice, the Note is callable in full or in part by the Company at any time after January 31, 2015. If the Average Daily Value of Trades (“ADVT”) during the prior 90 days as reported by Bloomberg is greater than $100,000, the Note is callable at a price of 105% of the Note’s par value, and if the ADVT is less than $100,000, the 9% Notes are callable at a price of 110% of the Note’s par value.
	In connection with the issuance of the 9% Notes, the holders of the 9% Notes received warrants to purchase 660,000 shares of the Company’s common stock at an exercise price of $0.45 per share, subject to adjustment for stock splits, reverse stock splits and stock dividends, and which are exercisable at any date prior to January 31, 2018, and were classified in equity. The fair value of the 9% Notes warrants was based on the Company’s closing stock price at the transaction date and inputs to the Black-Scholes option pricing model.
	NNA 8% Convertible Note
	The NNA 8% Convertible Note commitment provided for the Company to borrow up to $2,000,000. On July 31, 2014, the Company exercised its option to borrow $2,000,000, received $2,000,000 of proceeds and recorded a debt discount of $1,065,775 related to the fair value of a conversion feature liability and warrant liability discussed below. Borrowings bear interest at the rate of 8.0 % per annum payable semi-annually, and are convertible into shares of the Company’s common stock initially at $1.00 per share. The conversion price will be subject to adjustment in the event of subsequent down-round equity financings, if any, by the Company. The conversion feature included a non-standard anti-dilution feature that has been bifurcated and recorded as a conversion feature liability at the issuance date of $578,155. The fair value of the conversion feature liability issued in connection with 2014 NNA Financing 8% Convertible Note at July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 4.7 years, risk free rate of 1.6%, no dividends, volatility of 54.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing. In addition the Company was required to issue 1,000,000 warrants to NNA with an exercise price of $1.00 per share. The fair value of the warrant liability of $487,620 related to 1,000,000 common shares issuable in connection with NNA 8% Convertible Note at issuance date of July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.7 years, risk free rate of 2.1%, no dividends, volatility of 71.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing.
	Interest expense associated with the convertible notes payable consisted of the following:
		Three months ended				Six months ended
		September 30,				September 30,
		2014		2013		2014		2013
	Interest expense	$	52,856	$	111,387	$	77,881	$	185,619
	Amortization of loan fees and discount		60,884		29,025		97,322		80,766
		$	113,740	$	140,411	$	175,203	$	266,384

Income_Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	8. Income Taxes
	Deferred income taxes are provided on a liability method whereby deferred tax assets and liabilities are recognized for temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Significant management judgment is required in determining the Company’s provision for income taxes and the recoverability of the Company’s deferred tax assets. Such determination is based primarily on the Company’s historical taxable income, with some consideration given to the Company’s estimates of future taxable income by jurisdictions in which the Company operates and the period over which the Company’s deferred tax assets will be recoverable. Due to overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets as of September 30, 2014 and March 31, 2014. The Company is subject to U.S. federal income tax, as well as income tax of multiple state tax jurisdictions.
	ASC No. 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC No. 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC No. 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure requirements. The Company and its subsidiaries are currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended December 31, 2010 and later. The Company’s state income tax returns are open to audit under the statute of limitations for the years ended December 31, 2009 and later. The Company does not anticipate any material unrecognized tax benefits within the next twelve months.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Deficit	'
	9. Stockholders’ Equity
	Common Stock Placement
	On March 28, 2014, the Company entered into an equity and debt investment for up to $12.0 million with NNA. As part of the investment, the Company entered into an Investment Agreement with NNA, dated March 28, 2014 (the “Investment Agreement”), pursuant to which the Company sold NNA 2,000,000 shares of the Company’s common stock (the “Purchased Shares”) at a purchase price of $1.00 per share. In addition with the issuance of common shares, the Company issued to NNA 1,000,000 warrants to purchase the Company’s common stock for $1.00 per share. The Company used the Monte Carlo Method to value the warrants, which used the following inputs: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share and a 50% probability of down-round financing. The Company determined that the fair value of the shares issued was approximately $900,000, or approximately $0.45 per share. The Company also entered into a registration rights agreement (“RRA”) with NNA which requires the Company to file a registration statement to register its shares with the Securities and Exchange Commission no later than March 28, 2015. The RRA requires the Company to use commercially reasonable efforts to cause the RRA to be declared effective by the SEC. If the Initial Registration Statement is not filed with the SEC on or prior to the filing deadline the Company must pay to NNA an amount in Common Stock based upon its then fair market value, as liquidated damages equal to 1.50% of the aggregate purchase price paid by NNA.
	Equity Incentive Plans
	The Company’s amended 2010 Equity Incentive Plan (the “2010 Plan”) allowed the Board to grant up to 12,000,000 shares of the Company’s common stock, and provided for awards including incentive stock options, non-qualified options, restricted common stock, and stock appreciation rights. As of September 30, 2014, there were no shares available for grant.
	On April 29, 2013 the Company’s Board of Directors approved the Company’s 2013 Equity Incentive Plan (the “2013 Plan”), pursuant to which 5,000,000 shares of the Company’s common stock were reserved for issuance thereunder. The Company received approval of the 2013 Plan from the Company’s stockholders on May 19, 2013. The Company issues new shares to satisfy stock option and warrant exercises under the 2013 Plan. As of September 30, 2014 there were approximately 1,900,000 shares available for future grants under the 2013 Plan.
	Stock options and restricted common stock issued to non-employees as compensation for services to be provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair value of the option or share, whichever can be more clearly determined. The Company recognizes this expense over the period in which the services are provided.
	Share Issuances
	A summary of the Company’s restricted stock sold to employees, directors and consultants with a right of repurchase of unlapsed or unvested shares is as follows for the six months ended September 30, 2014:
						Weighted			Weighted			Weighted-
						Average			Average			average
						Remaining			Per Share			Per Share
						Vesting
						Life			Intrinsic			Grant Date
			Shares			(In years)			Value			Fair Value
	Unvested or unlapsed shares, beginning of period			907,407			1.3		$	-		$	0.41
	Granted			-			-			-			-
	Vested / lapsed			-611,111			-			-			-
	Forfeited			-			-			-			-
	Unvested or unlapsed shares, end of period			296,296			1.1		$	0.06		$	0.41
	Options
	In July 2014, the Company issued 565,000 options to acquire the Company’s common stock to certain employees and consultants. The Company determined that the weighted average fair value of the options of $0.24 per share using the Black-Scholes method with the following weighted-average inputs: term of 6 years, risk free rate of 1.63%, no dividends, volatility of 63.7%, share price of $0.54 per share.
	Stock option activity for the six months ended September 30, 2014 is summarized below:
			Shares			Weighted			Weighted			Weighted
						Average			Average			Average
						Per Share			Remaining			Per Share
						Exercise			Life			Intrinsic
						Price			(Years)			Value
	Balance, beginning of period			6,287,000		$	0.2			8.7		$	0.11
	Granted			565,000			1			-			-
	Cancelled			-100,000			-			-			-
	Exercised			-			-			-			-
	Expired			-			-			-			-
	Forfeited			-			-			-			-
	Balance, end of period			6,752,000		$	0.22			8.2		$	0.24
	Vested and exercisable, end of period			6,145,889		$	0.21			7.5		$	0.26
	ApolloMed ACO 2012 Equity Incentive Plan
	On October 18, 2012 ApolloMed ACO’s Board of Directors adopted the ApolloMed Accountable Care Organization, Inc. 2012 Equity Incentive Plan (the “ACO Plan”) and reserved 9,000,000 shares of ApolloMed ACO’s common stock for issuance thereunder. The purpose of the ACO Plan is to encourage selected employees, directors, consultants and advisers to improve operations and increase the profitability of ApolloMed ACO and encourage selected employees, directors, consultants and advisers to accept or continue employment or association with ApolloMed ACO.
	The following table summarizes the restricted stock award in the ACO Plan during the six months ended September 30, 2014:
			Shares			Weighted			Weighted			Weighted
						Average			Average			Average
						Remaining			Per Share			Per Share
						Vesting			Intrinsic			Fair Value
						Life			Value
						(Years)
	Balance, beginning of period			3,752,000			0.8		$	0.02		$	0.03
	Granted			112,000			-			-			0.78
	Released			-183,996			-			-			-
	Balance, end of period			3,680,004			0.6		$	0.73		$	0.05
	Vested and exercisable, end of period			2,461,694
	Awards of restricted stock under the Plan vest (i) one-third on the date of grant; (ii) one-third on the first anniversary of the date of grant, if the grantee has remained in service continuously until that date; and (iii) one-third on the second anniversary of the date of grant if the grantee has remained in service continuously until that date.
	As of September 30, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under the Company’s 2010 and 2013 Equity Plans, and the ACO Plan’s and the weighted-average period of years expected to recognize those costs are as follows:
	Common stock options		$	198,195
	Restricted stock		$	139,400
	ACO Plan restricted stock		$	57,179
	Stock-based compensation expense related to common stock and common stock option awards is recognized over their respective vesting periods and was included in the accompanying condensed consolidated statement of operations as follows:
			Three Months Ended						Six Months Ended
			September 30,						September 30,
			2014			2013			2014			2013
	Stock-based compensation expense:
	Cost of services		$	-17,822		$	86,630		$	10,921		$	575,509
	General and administrative			874,341			482,078			964,737			1,545,503
			$	856,519		$	568,708		$	975,658		$	2,121,012
Warrants
Warrants consisted of the following for the six months ended September 30, 2014:
		Weighted
		Average
		Per Share
		Intrinsic			Number of
		Value			warrants
Outstanding, beginning of period		$	0.02			7,145,000
Granted			-			2,000,000
Exercised			-			-
Cancelled			-			-
Outstanding, end of period		$	-			9,145,000
						Weighted
						average						Weighted
	Exercise Price Per		Warrants			remaining			Warrants			average
	Share		outstanding			contractual life			exercisable			exercise price per share
$	0.11485			1,250,000			1.8			1,250,000		$	0.1149
$	0.11485			250,000			1.8			250,000		$	0.1149
$	0.45			500,000			1.8			500,000		$	0.45
$	0.5			100,000			3.1			100,000		$	0.5
$	0.45			825,000			3.3			825,000		$	0.45
$	0.4			220,000			3.3			220,000		$	0.4
$	1			2,000,000			6.5			2,000,000		$	1
$	2			2,000,000			6.5			2,000,000		$	1
$	1			1,000,000			6.5			1,000,000		$	1
$	1			1,000,000			3.8			1,000,000		$	1
				9,145,000			4.8			9,145,000			0.97
In connection with the 2014 NNA Financing, NNA received warrants to purchase up to 2,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share and up to 2,000,000 shares at an exercise price of $2.00 per share, subject to adjustment for stock splits, reverse stock splits and stock dividends, and which are exercisable at any date prior to March 28, 2021. The warrants also contained down-round protection under which the exercise price of the warrants is subject to adjustment in the event the Company issues future common shares at a price below $0.90 per share. The Company determined that the warrants should be classified as liabilities under ASC 815-40, which requires the Company to determine the fair value of the warrants at the transaction date and at each subsequent reporting date (see Notes 2 and 6). Following the funding of the Convertible Note on July 30, 2014, additional warrants to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share that had been issued in connection with the 2014 NNA Financing became exercisable (see Note 6).
Authorized stock
At September 30, 2014 the Company was authorized to issue up to 100,000,000 shares of common stock. The Company is required to reserve and keep available out of the authorized but unissued shares of common stock such number of shares sufficient to effect the conversion of all outstanding shares of the 9% Senior Subordinated Callable Notes, the exercise of all outstanding warrants exercisable into shares of common stock, and shares granted and available for grant under the Company’s 2013 Plan. The amount of shares of common stock reserved for these purposes is as follows at September 30, 2014:
Common stock issued and outstanding		49,134,549
Conversion of 9% Notes		2,750,000
Conversion of 8% Notes		2,000,000
Warrants outstanding		9,145,000
Stock options outstanding		6,752,000
Remaining shares issuable under 2013 Equity Incentive Plan		1,900,000
		71,681,549

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	10. Commitments and Contingencies
	Regulatory Matters
	Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs. The Company believes that it is in compliance with all applicable laws and regulations.
	Legal
	On May 16, 2014, Lakeside Medical Group, Inc. and Regal Medical Group, Inc., two independent physician associations who compete with the Company in the greater Los Angeles area, filed an action against the Company and two affiliates of the Company, Maverick Medical Group, Inc. and ApolloMed Hospitalists, a Medical Corporation, in Los Angeles County Superior Court. The complaint alleged that the Company and its two affiliates made misrepresentations and engaged in other acts in order to improperly solicit physicians and patient-enrollees from Plaintiffs. The Complaint sought compensatory and punitive damages. On June 30, 2014, the Company and its affiliates filed a motion requesting the Court to stay the court proceeding and order the parties to arbitrate this dispute subject to existing arbitration agreements. On August 11, 2014, the Plaintiffs filed a request for dismissal without prejudice of the action. On August 12, 2014, the Plaintiffs served the Company and its affiliates with Demands for Arbitration before Judicial Arbitration Mediation Services in Los Angeles. The Company is currently examining the merits of the claims to be arbitrated, and it is too early to state whether the likelihood of an unfavorable outcome is probable or remote, or to estimate the potential loss if the outcome should be negative. The Company is aware that punitive damages previously sought in the court proceeding are not available in arbitration. The Company and its affiliates are preparing a defense to the allegations and the Company intends to vigorously defend the action.
	On August 28, 2014, Lakeside Medical Group, Inc. and Regal Medical Group, Inc., filed a similar lawsuit against Warren Hosseinion, the Chief Executive Officer of the Company. Dr. Hosseinion is defending the action and is currently being indemnified by the Company subject to the terms of an indemnification agreement and the Company’s charter. On September 9, 2014, Dr. Hosseinion filed a motion requesting the Court to stay the court proceeding and, pursuant to existing arbitration agreements, order the parties to arbitrate the dispute as part of the pending arbitration proceedings before JAMS (as discussed above). On October 29, 2014, the Plaintiffs filed a request for dismissal without prejudice of the action. Plaintiffs have informed the Company that Plaintiffs will be serving Dr. Hosseinion with Demands for Arbitration before Judicial Arbitration Mediation Services in Los Angeles. Dr. Hosseinion and the Company will seek to consolidate the proceedings against Dr. Hosseinion with the existing proceedings against the Company and its affiliates. The Company is currently examining the merits of the claims to be arbitrated, and it is too early to state whether the likelihood of an unfavorable outcome is probable or remote, or to estimate the potential loss if the outcome should be negative. The Company is aware that punitive damages previously sought in the court proceeding are not available in arbitration.
	In the ordinary course of the Company’s business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company’s affiliated hospitalists. The Company may also become subject to other lawsuits which could involve significant claims and/or significant defense costs. The Company believes, based upon the Company’s review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows in a future period
	Liability Insurance
	The Company believes that the Company’s insurance coverage is appropriate based upon the Company’s claims experience and the nature and risks of the Company’s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that the Company’s insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company’s affiliated professional organizations or the Company’s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company’s insurance coverage, will not have a material adverse effect on the Company’s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company’s business.
	Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may not continue to be available to the Company in future years at acceptable costs, and on favorable terms.

Subsequent_Events

Subsequent Events	6 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	11. Subsequent Events
	Lease Agreement
	The Company had a lease with EOP-700 North Brand, L.L.C., a Delaware limited liability company (“Landlord”),
	for 3,111 rentable square feet at 700 North Brand Boulevard, Suite No. 220, Glendale, California that commenced
	on December 16, 2011, and was set to expire on January 14, 2014. The lease was amended by a Commencement
	Letter dated February 6, 2012 and First Amendment dated November 8, 2012.
	On October 14, 2014, the lease was amended by a Second Amendment. The Second Amendment relocates the leased premises from Suite No. 220 to Suite Nos. 1400, 1425 and 1450, which collectively include 16,484 rentable square feet (the “New Premises”). The New Premises will be improved with an allowance of up to $659,360, provided by the Landlord, for construction and installation of equipment for the New Premises. Before the improved New Premises are available, the Company shall also use Suite No. 240 on a temporary basis. The Second Amendment also extends the term of the lease to be for approximately six years after the Company begins operations in the New Premises and increases the Company’s initial security deposit. The Second Amendment sets the New Premises base rent at $37,913.20 per month for the first year and schedules annual increases in base rent each year until the final rental year, which is capped at $43,957.33 per month. However, the base rent will be abated by up to $228,049.27 subject to other terms of the lease.
	Termination of a Material Definitive Agreement
	On October 23, 2014, the Company entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with Raouf Khalil (“Khalil”). Effective October 23, 2014, the Settlement Agreement terminates the Company’s obligations with respect to Khalil under that certain Stock Purchase Agreement, dated as of February 15, 2011 (the “Purchase Agreement”), among the Company, Aligned Healthcare Group, LLC (“Aligned LLC”), Aligned Healthcare Group – California, Inc. (“Aligned Corp.”), Khalil, Jamie McReynolds, M.D., BJ Reese and BJ Reese & Associates, LLC (collectively, the “Aligned Affiliates”), as amended by that certain First Amendment to Stock Purchase Agreement, dated as of July 8, 2011, among the Company, Aligned LLC, Aligned Corp., Khalil, Jamie McReynolds, M.D., BJ Reese and BJ Reese & Associates, LLC.
	Under the Settlement Agreement, the Company has reconveyed to Khalil all of the shares of Aligned Healthcare, Inc. (“AHI”) common stock that the Company acquired from Khalil under the Purchase Agreement. In addition, in consideration of a $10,000 cash payment, Khalil has reconveyed to the Company 500,000 shares of the Company’s common stock, constituting all of the shares that were issued to him under the Purchase Agreement. Following these reconveyances, the Company no longer owns any of the outstanding shares of AHI’s capital stock, and neither Khalil nor any of the other Aligned Affiliates own any shares of the Company’s capital stock.
	The Settlement Agreement was entered into by the parties to settle and resolve any claims, differences or disagreements that may exist between the Company and Khalil, and the Settlement Agreement provides for a mutual general release of all claims between the Company and Khalil.
	Purchase Agreement
	On October 27, 2014, Apollo Medical Management, Inc., a Delaware corporation (“AMM”), an affiliate of the Company made an initial capital contribution of $613,889 (the “Initial Contribution”) to Apollo Palliative Services LLC, a California limited liability company (the “APS”) in exchange for 51% of the membership interests of APS. APS used the Initial Contribution, in conjunction with funds provided by other investors in APS, to finance the closing payments described immediately below. In connection with this arrangement, the Company entered into a consulting agreement with one of the members. The term of this agreement is 6 years, and provides for the member to received $15,000 in cash per month, and be eligible to receive stock-based awards under the Company’s 2013 Equity Incentive Plan as determined by the Company’s Board of Directors
	Immediately prior to closing the transactions described below, and as condition precedent to APS closing the transactions, the selling equity owners in each transaction described below contributed specific equity interests to APS in return for interests in APS pursuant to contributions agreements.
	Subject to the terms and conditions of that certain Membership Interest Purchase Agreement (the “BCHC Agreement”), dated October 27, 2014, by and among APS, the Company, the sole members of Best Choice Hospice Care, LLC, a California limited liability company (“BCHC”), and BCHC, APS agreed to purchase all of the remaining membership interests in BCHC for $900,000 in cash, subject to reduction if BCHC’s working capital was less than $145,000 as of the closing of the transaction. APS agreed to pay a contingent payment of up to a further $400,000 (the “BCHC Contingent Payment”) to one seller and one employee of BCHC. The BCHC Contingent Payment will be paid in two installments of $100,000 to each of the seller and the employee within sixty days of each of the first and second anniversaries of the transaction, and is contingent upon, as of each applicable date, the seller’s and the employee’s employment, as applicable, continuing or having been terminated without cause and, for the employee, meeting certain productivity targets. The Company absolutely, unconditionally and irrevocably guaranteed payment of the BCHC Contingent Payment if APS fails to make any payment.
	Subject to the terms and conditions of that certain Stock Purchase Agreement (the “HCHHA Agreement”), dated October 27, 2014, by and among APS, the sole shareholder of Holistic Care Home Health Agency, Inc., a California corporation (“HCHHA”), and HCHHA, APS agreed to purchase all of the remaining shares of HCHHA for $300,000 in cash, subject to reduction if HCHHA’s working capital was less than $50,000 as of the closing of the transaction. APS agreed to pay a contingent payment of up to a further $150,000 (the “HCHHA Contingent Payment”). The HCHHA Contingent Payment will be paid in two installments of $75,000 to the seller within sixty days of each of the first and second anniversaries of the transaction, and is contingent upon, as of each applicable date, the seller’s employment continuing or having been terminated without cause and meeting certain productivity targets.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Accounting Principles	'
	Accounting Principles
	These condensed consolidated statements reflect all adjustments, consisting of normal recurring adjustments, which, in management’s opinion, are necessary, and should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2014 as filed with the Securities and Exchange Commission (“SEC”) on May 8, 2014.
Principles of Consolidation	'
	Principles of Consolidation
	The Company’s consolidated financial statements include the accounts of (1) Apollo Medical Holdings, Inc. and its wholly owned subsidiaries AMM, PCCM, and VMM, (2) the Company’s controlling interest in ApolloMed ACO, and APS, which is a newly formed entity with no operations to date to provide home health and hospice medical services and in which a non-controlling interest in APS contributed $550,000 in cash; and (3) PPCs managed under long-term management service agreements including AMH, MMG, ACC, LALC, Hendel, AKM and SCHC. Some states have laws that prohibit business entities, such as ApolloMed, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the corporate practice of medicine), or engaging in certain arrangements with physicians, such as fee-splitting. In California, the Company operates by maintaining long-term management service agreements with the PPCs, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide hospitalist services. Under the management agreements, the Company provides and performs all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. Each management agreement typically has a term from 10 to 20 years unless terminated by either party for cause. The management agreements are not terminable by the PPCs, except in the case of material breach or bankruptcy of the respective PPM.
	Through the management agreements and the Company’s relationship with the stockholders of the PPCs, the Company has exclusive authority over all non-medical decision making related to the ongoing business operations of the PPCs. Consequently, the Company consolidates the revenue and expenses of each PPC from the date of execution of the applicable management agreement.
	All intercompany balances and transactions have been eliminated in consolidation.
Revenue Recognition	'
	Revenue Recognition
	Revenue consists of contracted, fee-for-service, and capitation revenue. Revenue is recorded in the period in which services are rendered. Revenue is principally derived from the provision of healthcare staffing services to patients within healthcare facilities. The form of billing and related risk of collection for such services may vary by customer. The following is a summary of the principal forms of the Company’s billing arrangements and how net revenue is recognized for each.
	Contracted revenue
	Contracted revenue represents revenue generated under contracts for which the Company provides physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates. Revenue in such cases is recognized as the hours are worked by the Company’s staff and contractors. Additionally, contract revenue also includes supplemental revenue from hospitals where the Company may have a fee-for-service contract arrangement or provide physician advisory services to the medical staff at a specific facility. Contract revenue for the supplemental billing in such cases is recognized based on the terms of each individual contract. Such contract terms generally either provides for a fixed monthly dollar amount or a variable amount based upon measurable monthly activity, such as hours staffed, patient visits or collections per visit compared to a minimum activity threshold. Such supplemental revenues based on variable arrangements are usually contractually fixed on a monthly, quarterly or annual calculation basis considering the variable factors negotiated in each such arrangement. Such supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement. Additionally, the Company derives a portion of the Company’s revenue as a contractual bonus from collections received by the Company’s partners and such revenue is contingent upon the collection of third-party billings. These revenues are not considered earned and therefore not recognized as revenue until actual cash collections are achieved in accordance with the contractual arrangements for such services.
	Fee-for-service revenue
	Fee-for-service revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company’s contracted and employed physicians. Under the fee-for-service arrangements, the Company bills patients for services provided and receives payment from patients or their third-party payers. Fee-for-service revenue is reported net of contractual allowances and policy discounts. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. Fee-for-service revenue is recognized in the period in which the services are rendered to specific patients and reduced immediately for the estimated impact of contractual allowances in the case of those patients having third-party payor coverage. The recognition of net revenue (gross charges less contractual allowances) from such visits is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company’s billing systems as well as an estimate of the revenue associated with medical services.
	Capitation revenue
	Capitation revenue (net of capitation withheld to fund risk share deficits) is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted health maintenance organizations (each, an “HMO”) finalizing of monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a provider service agreement (PSA) or capitated arrangements directly made with various managed care providers including HMO’s. Capitation revenue under the PSA and HMO contracts is prepaid monthly to the Company based on the number of enrollees electing the Company as their healthcare provider. Additionally, Medicare pays capitation using a “Risk Adjustment model,” which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on an interim basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.
	HMO contracts also include provisions to share in the risk for enrollee hospitalization, whereby the Company can earn additional incentive revenue or incur penalties based upon the utilization of hospital services. Typically, any shared risk deficits are not payable until and unless the Company generates future risk sharing surpluses, or if the HMO withholds a portion of the capitation revenue to fund any risk share deficits. At the termination of the HMO contract, any accumulated risk share deficit is typically extinguished. Due to the lack of access to information necessary to estimate the related costs, shared-risk amounts receivable from the HMOs are only recorded when such amounts are known. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following fiscal year.
	In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. These incentives, which are included in other revenues, are generally recorded in the third and fourth quarters of the fiscal year and are recorded when such amounts are known.
	Under full risk capitation contracts, an affiliated hospital entered into agreements with several HMOs, pursuant to which, the affiliated hospital will provide hospital, medical, and other healthcare services to enrollees under a fixed capitation arrangement ("Capitation Arrangement"). Under the risk pool sharing agreement, the affiliated hospital and medical group agreed to establish a Hospital Control Program to serve the enrollees, pursuant to which, the medical group is allocated a 90% residual interest in the profit or loss, after deductions for costs to affiliated hospitals. The Company participates in the full risk programs under the terms of the PSA, whereby the Company is wholly liable for the deficits allocated to the medical group under the arrangement. The related liability is included in medical liabilities in the accompanying unaudited condensed consolidated balance sheets at September 30 and March 31, 2014 (see "Medical Liabilities" in this Note 2, below).
	Medicare Shared Savings Program Revenue
	The Company through its subsidiary, ApolloMed ACO, participates in the MSSP sponsored by the Centers for Medicare & Medicaid Services (“CMS”). The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated by the ACO participant relative to the ACO participants trailing 24 month medical service history. The MSSP is a newly formed program with minimal history of payments to ACO participants. The Company considers revenue, if any, under the MSSP, as contingent upon the realization of program savings as determined by CMS, and are not considered earned and therefore are not recognized as revenue until notice from CMS that cash payments are to be imminently received.
	During the second quarter of 2014, CMS announced that ApolloMed ACO generated $10.98 million in program savings from cost savings created in connection with rendering medical services to Medicare patients in 2012. In connection with these cost savings, the Company earned $5.38 million which has been reported in the line items “Net Revenue and “other receivable” in the September 30, 2014 condensed consolidated financial statements. Revenue from the MSSP is determined and awarded annually, and the Company does not anticipate additional revenue in fiscal 2015. Future ACO program savings for services performed in calendar year 2013 and 2014 are not estimable.
Concentrations	'
	Concentrations
	Excluding the MSSP related revenue, the Company had no major payors during the three months ended September 30, 2014 which contributed more than 10% of net revenues, and had three major payors during the three months ended September 30, 2013 which contributed 16.1%, 16.1% and 16.8% of net revenues, respectively. During the six months ended September 30, 2014, excluding the MSSP related revenue, the Company had no major payors which contributed more than 10% of net revenues and had three major payors during the six months ended September 30, 2013 which contributed 15.8%, 16.1% and 17.6% of net revenues, respectively.
	The Company had one major payor that accounted for 12.5 % of accounts receivable as of September 30, 2014, and two major payors that accounted for 21.7% and 9.6% of accounts receivable, respectively, as of March 31, 2014.
Cash Equivalents and Marketable Securities	'
	Cash Equivalents and Marketable Securities
	The Company’s cash equivalents consist of bank demand deposits and highly liquid investments with original maturities of three months or less from the original purchase date.
	The Company’s marketable securities consist of our holdings in equity securities and mutual funds. These are classified as available-for-sale, which are measured each reporting period at fair value, with any unrealized change in value reflected in other comprehensive income or loss, and realized gains or losses in the statement of operations in the accompany condensed consolidated statements of operations and comprehensive income (loss). Other than temporary impairments are evaluated for securities that have been in a continuous unrealized loss position longer than one year.
	The following is a summary of cash equivalents and marketable securities:
	As of September 30, 2014			Gross		Gross		Estimated		Cash and		Marketable
				Unrealized		Unrealized		Fair		Cash		Securities
		Cost		Gain		Loss		Value		Equivalents		(all current)
	Bank demand deposits	$	3,856,285	$	-	$	-	$	3,856,285	$	3,856,285	$	-
	Money market funds		93,840		-		-		93,840		93,840		-
	Mutual funds		148,028		966		-		148,994		-		148,994
	Equity securities		241,065		32,122		-		273,187		-		273,187
		$	4,339,218	$	33,088	$	-	$	4,372,306	$	3,950,125	$	422,181
	As of March 31, 2014			Gross		Gross		Estimated		Cash and
				Unrealized		Unrealized		Fair		Cash
		Cost		Gain		Loss		Value		Equivalents
	Bank demand deposits	$	6,831,478		-		-	$	6,831,478	$	6,831,478
		$	6,831,478	$	-	$	-	$	6,831,478	$	6,831,478
Medical Liabilities	'
	Medical Liabilities
	The Company is responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees under risk-pool arrangements. The Company provides integrated care to health plan enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements, company-operated clinics and staff physicians. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services in the accompanying condensed consolidated statements of operations and comprehensive loss. Costs for operating medical clinics, including the salaries of medical and non-medical personnel and support costs, are also recorded in cost of services.
	An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying condensed consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates of incurred but not reported claims (“IBNR”). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. The Company has a $20,000 per member professional stop-loss, none on institutional risk pools. Any adjustments to reserves are reflected in current operations.
	The Company’s IBNR reserve for the six months ended September 30, 2014 was as follows:
	Balance, beginning of period	$	274,000
	Incurred health care costs:
	Current year		1,566,856
	Prior years		-
	Total incurred health care costs		1,566,856
	Acquired medical liabilities (see Note 3 )		292,309
	Claims paid:
	Current year		-997,390
	Prior years		-64,482
	Total claims paid		-1,061,872
	Adjustments		-197,938
	Balance, end of period	$	873,355
	The Company’s accrual for its risk-pool liability for the six months ended September 30, 2014 was as follows:
	Balance, beginning of period	$	278,561
	Acquired medical liabilities (see Note 3)		128,848
	Claims paid:		-
	Accrual for net deficit from full risk capitation contracts		361,733
	Balance, end of period	$	769,142
	The Company’s total medical liability at September 30, 2014 and March 31, 2014 was $1,642,497 and $552,561, respectively.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s accounting for Fair Value Measurement and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The hierarchy consists of three levels:
	Level one — Quoted market prices in active markets for identical assets or liabilities;
	Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
	Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.
	The fair values of the Company’s financial instruments are measured on a recurring basis. The carrying amount reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates fair value because of the short-term maturity of those instruments. The carrying amount for borrowings under the NNA Term Loan and the Convertible Notes approximates fair value which is determined by using interest rates that are available for similar debt obligations with similar terms at the balance sheet date.
	Warrant liability
	The fair value of the warrant liability issued in connection with 2014 NNA Financing at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.5 years, risk free rate of 2.1%, no dividends, volatility of 72.2%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing. The fair value of the warrant liability at March 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 50% probability of down-round financing.
	The fair value of the warrant liability of $487,620 related to 1,000,000 common shares issuable in connection with NNA 8% Convertible Note at issuance date of July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.7 years, risk free rate of 2.1%, no dividends, volatility of 71.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing.
	Holdback liability
	The holdback liability (see Note 3) fair value was determined based on the probability adjusted cash consideration, discounted at the Company's cost of debt.
	Conversion feature liability
	The fair value of the conversion feature liability issued in connection with 2014 NNA Financing 8% Convertible Note at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 4.5 years, risk free rate of 1.6%, no dividends, volatility of 55.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability that the Company will participate in a “down-round” financing at price per share lower than the initial NNA Financing 8% Convertible Note conversion price of $1.00 per share.
	The carrying amounts and fair values of the Company's financial instruments are presented below as of:
	September 30, 2014
		Fair Value Measurements
		Level 1		Level 2		Level 3		Total
	Assets:
	Money market currency funds	$	-	$	93,840	$	-	$	93,840
	Mutual funds		-		148,994		-		148,994
	Equity securities		273,187		-		-		273,187
		$	273,187	$	242,834	$	-	$	516,021
	Liabilities:
	Warranty liability	$	-	$	-	$	2,750,480	$	2,750,480
	Holdback consideration		-		-		136,822		136,822
	Conversion feature liability		-		-		547,784		547,784
		$	-	$	-	$	3,435,086	$	3,435,086
	March 31, 2014
		Fair Value Measurements
		Level 1		Level 2		Level 3		Total
	Liabilities:
	Warrant liability	$	-	$	-	$	2,354,624	$	2,354,624
		$	-	$	-	$	2,354,624	$	2,354,624
	The following summarizes the activity of Level 3 inputs measured on a recurring basis for the three and six months ended September 30, 2014:
		Three months			Six months
	Balance, beginning of period	$	2,521,451	$	2,354,624
	Warrant liability incurred (Note 7)		487,620		487,620
	Change in warrant liability		-121,769		-91,764
	Holdback consideration		-		136,822
	Conversion feature liability incurred (Note 7)		578,155		578,155
	Change in conversion feature liability		-30,371		-30,371
	Balance, end of period	$	3,435,086	$	3,435,086
	The unrealized gain on changes in fair value of warrant and conversion feature liability is included in the accompanying condensed consolidated statement of operations and comprehensive loss.
Non-controlling Interest	'
	Non-controlling Interest
	The non-controlling interest recorded in the Company’s condensed consolidated financial statements represents the pre-acquisition equity of those PPC’s in which the Company has determined that it has a controlling financial interest and for which consolidation is required as a result of management contracts entered into with these entities. The nature of these contracts provide the Company with a monthly management fee to provide the services described above, and as such, the adjustments to non-controlling interests in any period subsequent to initial consolidation would relate to either capital contributions or distributions by the non-controlling parties as well as income or losses attributable to certain non-controlling interests.
Basic and Diluted Earnings per Share	'
	Basic and Diluted Earnings per Share
	Basic net income (loss) per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted net income (loss) per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for secured convertible notes, and the treasury stock method for options and warrants.
	The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would be anti-dilutive:
			Three Months Ended September 30,				Six Months Ended September 30,
			2014		2013		2014		2013
	Options		-		4,373,687		3,657,216		4,547,125
	Warrants		-		1,428,067		1,495,803		1,535,402
	9% Convertible Notes		799,523		674,528		748,824		785,714
			799,523		6,476,282		5,901,843		6,868,241
New Accounting Standards	'
	New Accounting Standards
	In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40). The guidance in this ASU requires disclosure of uncertainties about an entity’s ability to continue as a going concern even if an entity’s liquidation is not imminent. There may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting and this guidance should be followed to determine whether to disclose information about the relevant conditions and events. This guidance is effective for the Company on December 31, 2016 and the adoption of this standard is not expected to have a significant impact on its condensed consolidated financial statements or notes thereto.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with United States GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may materially differ from these estimates under different assumptions or conditions.
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made to the accompanying March 31, 2014 condensed consolidated financial statements to conform them to the September 30, 2014 presentation.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Schedule Of Cash Equivalents And Marketable Securities	'
	The following is a summary of cash equivalents and marketable securities:
	As of September 30, 2014			Gross		Gross		Estimated		Cash and		Marketable
				Unrealized		Unrealized		Fair		Cash		Securities
		Cost		Gain		Loss		Value		Equivalents		(all current)
	Bank demand deposits	$	3,856,285	$	-	$	-	$	3,856,285	$	3,856,285	$	-
	Money market funds		93,840		-		-		93,840		93,840		-
	Mutual funds		148,028		966		-		148,994		-		148,994
	Equity securities		241,065		32,122		-		273,187		-		273,187
		$	4,339,218	$	33,088	$	-	$	4,372,306	$	3,950,125	$	422,181
	As of March 31, 2014			Gross		Gross		Estimated		Cash and
				Unrealized		Unrealized		Fair		Cash
		Cost		Gain		Loss		Value		Equivalents
	Bank demand deposits	$	6,831,478		-		-	$	6,831,478	$	6,831,478
		$	6,831,478	$	-	$	-	$	6,831,478	$	6,831,478
Schedule of Medical Payables	'
	The Company’s IBNR reserve for the six months ended September 30, 2014 was as follows:
	Balance, beginning of period	$	274,000
	Incurred health care costs:
	Current year		1,566,856
	Prior years		-
	Total incurred health care costs		1,566,856
	Acquired medical liabilities (see Note 3 )		292,309
	Claims paid:
	Current year		-997,390
	Prior years		-64,482
	Total claims paid		-1,061,872
	Adjustments		-197,938
	Balance, end of period	$	873,355
Company Accrual Risk Pool Liability	'
	The Company’s accrual for its risk-pool liability for the six months ended September 30, 2014 was as follows:
	Balance, beginning of period	$	278,561
	Acquired medical liabilities (see Note 3)		128,848
	Claims paid:		-
	Accrual for net deficit from full risk capitation contracts		361,733
	Balance, end of period	$	769,142
Fair Value Measurements, Recurring and Nonrecurring	'
	The carrying amounts and fair values of the Company's financial instruments are presented below as of:
	September 30, 2014
		Fair Value Measurements
		Level 1		Level 2		Level 3		Total
	Assets:
	Money market currency funds	$	-	$	93,840	$	-	$	93,840
	Mutual funds		-		148,994		-		148,994
	Equity securities		273,187		-		-		273,187
		$	273,187	$	242,834	$	-	$	516,021
	Liabilities:
	Warranty liability	$	-	$	-	$	2,750,480	$	2,750,480
	Holdback consideration		-		-		136,822		136,822
	Conversion feature liability		-		-		547,784		547,784
		$	-	$	-	$	3,435,086	$	3,435,086
	March 31, 2014
		Fair Value Measurements
		Level 1		Level 2		Level 3		Total
	Liabilities:
	Warrant liability	$	-	$	-	$	2,354,624	$	2,354,624
		$	-	$	-	$	2,354,624	$	2,354,624
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation	'
	The following summarizes the activity of Level 3 inputs measured on a recurring basis for the three and six months ended September 30, 2014:
		Three months			Six months
	Balance, beginning of period	$	2,521,451	$	2,354,624
	Warrant liability incurred (Note 7)		487,620		487,620
	Change in warrant liability		-121,769		-91,764
	Holdback consideration		-		136,822
	Conversion feature liability incurred (Note 7)		578,155		578,155
	Change in conversion feature liability		-30,371		-30,371
	Balance, end of period	$	3,435,086	$	3,435,086
Basic and Diluted Earnings per Share	'
	The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would be anti-dilutive:
			Three Months Ended September 30,				Six Months Ended September 30,
			2014		2013		2014		2013
	Options		-		4,373,687		3,657,216		4,547,125
	Warrants		-		1,428,067		1,495,803		1,535,402
	9% Convertible Notes		799,523		674,528		748,824		785,714
			799,523		6,476,282		5,901,843		6,868,241

Acquisitions_Tables

Acquisitions (Tables)	6 Months Ended
	Sep. 30, 2014
Business Acquisition [Line Items]	'
Weighted-average amortization period for intangible assets acquired	'
	The intangible assets acquired consisted of the following:
		Life		Additions
		(yrs)
	Network relationships	5		$	910,000
	Trade name	5			110,000
	Non-compete agreements	3			101,000
				$	1,121,000
AKM	'
Business Acquisition [Line Items]	'
Schedule Of Business Acquisitions By Acquisition Consideration Transferred	'
	The acquisition-date fair value of the consideration transferred was as follows:
	Cash consideration	$	140,000
	Fair value of holdback consideration due to seller		136,822
	Total purchase consideration	$	276,822
Schedule of Purchase Prices Allocations	'
	Under the acquisition method of accounting, the total purchase price was allocated to AKM’s net tangible assets based on their estimated fair values as of the closing date. The preliminary allocation of the total purchase price to the net assets acquired and included in the Company’s condensed consolidated balance sheet is as follows:
	Cash and cash equivalents	$	356,359
	Marketable securities		389,094
	Accounts receivable		27,217
	Prepaid expenses and other assets		26,311
	Intangibles		156,000
	Goodwill		-216,563
	Accounts payable and accrued liabilities		-40,439
	Medical payables		-421,157
	Net assets acquired	$	276,822
SCHC	'
Business Acquisition [Line Items]	'
Schedule Of Business Acquisitions By Acquisition Consideration Transferred	'
	The acquisition-date fair value of the consideration transferred was as follows:
	Cash consideration	$	2,428,391
	Fair value of warrant consideration		132,000
		$	2,560,391
Schedule of Purchase Prices Allocations	'
	The preliminary allocation of the total purchase price to the net assets acquired and liabilities assumed and included in the Company’s condensed consolidated balance sheet at September 30, 2014 is as follows:
	Cash and cash equivalents	$	264,601
	Accounts receivable		840,433
	Receivable from affiliate		67,714
	Prepaid expenses and other current assets		82,430
	Property and equipment		584,377
	Identifiable intangible assets		1,121,000
	Goodwill		161,559
	Other assets		66,762
	Total assets acquired		3,188,876
	Accounts payable and accrued liabilities		134,427
	Note payable to financial institution		463,582
	Deferred tax liability		30,477
	Total liabilities assumed		628,485
	Net assets acquired	$	2,560,391
AKM & SCHC	'
Business Acquisition [Line Items]	'
Business Acquisition, Pro Forma Information	'
	The following unaudited pro forma results of operations for the three and six months ended September 30, 2014 assume both the AKM and SCHC acquisitions had occurred on April 1, 2014, and for the six months ended September 30, 2013 assume the acquisitions had occurred on April 1, 2013:
		Three months ended September 30,					Six months ended September 30,
		2014			2013		2014		2013
		(unaudited)			(unaudited)		(unaudited)		(unaudited)
	Net revenue	$	11,899,142		$	4,477,640	$	17,956,326	$	9,135,956
	Net income (loss)	$	1,410,936		$	-1,067,658	$	-209,441	$	-3,054,008
	Basic income (loss) per share	$	0.03		$	-0.02	$	0	$	-0.08
	Diluted income (loss) per share	$	0.03		$	-0.02	$	0	$	-0.08

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill Activity	'
	The following is a summary of goodwill activity for the six months ended September 30, 2014:
	Balance, beginning of period		$	494,700
	Acquisition of AKM			-216,565
	Acquisition of SCHC			161,559
	Balance, end of period		$	439,694
Other Intangible Assets	'
	Other intangible assets consisted of the following:
		Weighted-average life		Balance at		Additions		Balance at
		(Yrs)		31-Mar-14				30-Sep-14
	Intangible assets:
	Exclusivity	4		$	40,000	$	-	$	40,000
	Non-compete	4			28,400		120,000		148,400
	Payor relationships	5			-		94,000		94,000
	Network relationships	5			-		910,000		910,000
	Trade name	5			-		153,000		153,000
	Totals				68,400		1,277,000		1,345,400
	Accumulated amortization				-8,773		-130,308		-139,081
	Total other intangibles, net			$	59,627	$	1,146,692	$	1,206,319
Future Amortization Expense	'
	Future amortization expense is estimated to be as follows for the period from October 1, 2014 to March 31, 2015 and for each for the five years ending March 31 thereafter:
	October 1, 2014 to March 31, 2015	$	255,000
	2016	$	326,000
	2017	$	259,000
	2018	$	192,000
	2019	$	125,000
	Thereafter	$	46,000

Accounts_Payable_and_Accrued_L1

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accounts payable and accrued liabilities	'
	Accounts payable and accrued liabilities consisted of the following:
		September 30,		March 31,
		2014		2014
	Accounts payable	$	1,456,796	$	824,334
	Physician share of MSSP ACO savings		1,400,000		-
	Accrued compensation		809,772		546,078
	Income taxes payable		85,477		4,149
	Accrued interest		28,049		19,780
	Accrued professional fees		12,550		52,699
		$	3,792,645	$	1,447,040

Notes_and_Lines_of_Credit_Paya1

Notes and Lines of Credit Payable (Tables)	6 Months Ended
	Sep. 30, 2014
Notes Payable [Abstract]	'
Schedule of Notes and lines of credit payable	'
	Notes and line of credit payable consist of the following:
		September 30,		March 31,
		2014		2014
	Term loan payable to NNA due March 28, 2019, net of debt discount of $1,183,856 (September 30, 2014) and $1,305,435 (March 31, 2014)	$	5,553,644	$	5,694,565
	Unsecured revolving line of credit due to financial institution due June 5, 2015		94,764		94,764
		$	5,648,408	$	5,789,329
Schedule of Interest Expense Associated with Notes Payable	'
	Interest expense associated with the notes and lines of credit payable consisted of the following:
		Three months ended				Six months ended
		September 30,				September 30,
		2014		2013		2014		2013
	Interest expense	$	143,845	$	25,089	$	287,998	$	56,087
	Amortization of loan fees and discount		71,673		35,061		142,924		39,780
		$	215,518	$	60,151	$	430,922	$	95,868

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Sep. 30, 2014
Convertible Notes [Abstract]	'
Schedule of Long-term Debt Instruments	'
	Convertible notes payable consist of the following:
		September		March
		30,		31,
		2014		2014
	9% Senior Subordinated Convertible Notes due February 15, 2016, net of debt discount of $99,973 (September 30, 2014) and $137,393 (March 31, 2014)	$	1,000,398	$	962,978
	8% Senior Subordinated Convertible Note Payable to NNA due March 28, 2019, net of debt discount of $1,046,811		953,189		-
		$	1,953,587	$	962,978
Schedule Of Debt Instruments Interest Expense	'
	Interest expense associated with the convertible notes payable consisted of the following:
		Three months ended				Six months ended
		September 30,				September 30,
		2014		2013		2014		2013
	Interest expense	$	52,856	$	111,387	$	77,881	$	185,619
	Amortization of loan fees and discount		60,884		29,025		97,322		80,766
		$	113,740	$	140,411	$	175,203	$	266,384

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Nonvested Share Activity	'
	A summary of the Company’s restricted stock sold to employees, directors and consultants with a right of repurchase of unlapsed or unvested shares is as follows for the six months ended September 30, 2014:
						Weighted			Weighted			Weighted-
						Average			Average			average
						Remaining			Per Share			Per Share
						Vesting
						Life			Intrinsic			Grant Date
			Shares			(In years)			Value			Fair Value
	Unvested or unlapsed shares, beginning of period			907,407			1.3		$	-		$	0.41
	Granted			-			-			-			-
	Vested / lapsed			-611,111			-			-			-
	Forfeited			-			-			-			-
	Unvested or unlapsed shares, end of period			296,296			1.1		$	0.06		$	0.41
Stock Option Transactions Under Stock Option Plans	'
	Stock option activity for the six months ended September 30, 2014 is summarized below:
			Shares			Weighted			Weighted			Weighted
						Average			Average			Average
						Per Share			Remaining			Per Share
						Exercise			Life			Intrinsic
						Price			(Years)			Value
	Balance, beginning of period			6,287,000		$	0.2			8.7		$	0.11
	Granted			565,000			1			-			-
	Cancelled			-100,000			-			-			-
	Exercised			-			-			-			-
	Expired			-			-			-			-
	Forfeited			-			-			-			-
	Balance, end of period			6,752,000		$	0.22			8.2		$	0.24
	Vested and exercisable, end of period			6,145,889		$	0.21			7.5		$	0.26
Summary of Restricted Stock Award	'
	The following table summarizes the restricted stock award in the ACO Plan during the six months ended September 30, 2014:
			Shares			Weighted			Weighted			Weighted
						Average			Average			Average
						Remaining			Per Share			Per Share
						Vesting			Intrinsic			Fair Value
						Life			Value
						(Years)
	Balance, beginning of period			3,752,000			0.8		$	0.02		$	0.03
	Granted			112,000			-			-			0.78
	Released			-183,996			-			-			-
	Balance, end of period			3,680,004			0.6		$	0.73		$	0.05
	Vested and exercisable, end of period			2,461,694
Total Unrecognized Compensation Costs Related To Non-Vested Stock-Based Compensation Arrangements	'
	As of September 30, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under the Company’s 2010 and 2013 Equity Plans, and the ACO Plan’s and the weighted-average period of years expected to recognize those costs are as follows:
	Common stock options		$	198,195
	Restricted stock		$	139,400
	ACO Plan restricted stock		$	57,179
Summary of Stock Based Compensation Expense Related To Restricted Stock and Option Awards	'
	Stock-based compensation expense related to common stock and common stock option awards is recognized over their respective vesting periods and was included in the accompanying condensed consolidated statement of operations as follows:
			Three Months Ended						Six Months Ended
			September 30,						September 30,
			2014			2013			2014			2013
	Stock-based compensation expense:
	Cost of services		$	-17,822		$	86,630		$	10,921		$	575,509
	General and administrative			874,341			482,078			964,737			1,545,503
			$	856,519		$	568,708		$	975,658		$	2,121,012
Warrants Outstanding	'
	Warrants consisted of the following for the six months ended September 30, 2014:
			Weighted
			Average
			Per Share
			Intrinsic			Number of
			Value			warrants
	Outstanding, beginning of period		$	0.02			7,145,000
	Granted			-			2,000,000
	Exercised			-			-
	Cancelled			-			-
	Outstanding, end of period		$	-			9,145,000
							Weighted
							average						Weighted
		Exercise Price Per		Warrants			remaining			Warrants			average
		Share		outstanding			contractual life			exercisable			exercise price per share
	$	0.11485			1,250,000			1.8			1,250,000		$	0.1149
	$	0.11485			250,000			1.8			250,000		$	0.1149
	$	0.45			500,000			1.8			500,000		$	0.45
	$	0.5			100,000			3.1			100,000		$	0.5
	$	0.45			825,000			3.3			825,000		$	0.45
	$	0.4			220,000			3.3			220,000		$	0.4
	$	1			2,000,000			6.5			2,000,000		$	1
	$	2			2,000,000			6.5			2,000,000		$	1
	$	1			1,000,000			6.5			1,000,000		$	1
	$	1			1,000,000			3.8			1,000,000		$	1
					9,145,000			4.8			9,145,000			0.97
Amount of Shares of Common Stock Reserved	'
	The amount of shares of common stock reserved for these purposes is as follows at September 30, 2014:
	Common stock issued and outstanding		49,134,549
	Conversion of 9% Notes		2,750,000
	Conversion of 8% Notes		2,000,000
	Warrants outstanding		9,145,000
	Stock options outstanding		6,752,000
	Remaining shares issuable under 2013 Equity Incentive Plan		1,900,000
			71,681,549

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jul. 31, 2014

Jul. 31, 2014

Mar. 28, 2014

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Jul. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Warrant [Member]

Convertible Notes Payable [Member]

2014 NNA Financing

2014 NNA Financing

Maximum [Member]

Minimum [Member]

Three Major Customers

Three Major Customers

NNA 8 Convertible Notes

Customer A

Customer A

Customer A

Customer A

Customer B

Customer B

ApolloMed ACO

ApolloMed ACO

Three Major Customers

Three Major Customers

Three Major Customers

Three Major Customers

Three Major Customers

Summary Of Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Management agreement, initial term

'

'

'

'

'

'

'

'

'

'

'20 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

Revenue Of Major Customers Percentage Of Total Revenue

'

'

'

'

'

'

'

'

'

'

'

'

16.10%

17.60%

'

10.00%

10.00%

16.10%

15.80%

16.80%

16.10%

'

'

Percentage Of Accounts Receivable From Customers

'

'

'

'

'

'

'

'

'

'

'

'

'

9.60%

'

'

12.50%

'

12.50%

'

21.70%

'

'

Expected term

'6 years 8 months 12 days

'6 years

'7 years

'

'

'

'

'

'6 years 6 months

'7 years

'

'

'

'

'4 years 6 months

'

'

'

'

'

'

'

'

Risk free interest rate

2.10%

1.63%

2.31%

'

'

'

'

'

2.10%

2.31%

'

'

'

'

1.60%

'

'

'

'

'

'

'

'

Expected volatility rate

71.80%

63.70%

71.40%

'

'

'

'

'

'

71.40%

'

'

'

'

55.40%

'

'

'

'

'

'

'

'

Expected dividend rate

'

0.00%

'

'

'

'

'

'

72.20%

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

Share Price

$0.49

$0.49

'

'

'

'

'

'

$0.45

$0.45

'

'

'

'

$0.45

'

'

'

'

'

'

'

'

Percentage For Down round financing

'

100.00%

'

'

'

'

'

'

100.00%

50.00%

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

Health Care Organization, Patient Service Revenue

'

'

'

$20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,380,000

$10,980,000

Medical Liability Current

'

'

'

1,642,497

'

552,561

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

non-controlling interest

'

'

'

550,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liability

'

'

'

'

'

'

$487,620

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Shares Issuable

1,000,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

8.00%

8.00%

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash_Equivalents_and_Marketabl

Cash Equivalents and Marketable Securities (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cost	$4,339,218	$6,831,478	'	'
Gross Unrealized Gain	33,088	0	'	'
Gross Unrealized Loss	0	0	'	'
Available-for-sale Securities, Debt Securities, Current	4,372,306	6,831,478	'	'
Cash and Cash Equivalents, at Carrying Value, Total	3,950,125	6,831,478	1,075,262	1,094,973
Marketable Securities	422,181	0	'	'
Mutual Funds [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cost	148,028	'	'	'
Gross Unrealized Gain	966	'	'	'
Gross Unrealized Loss	0	'	'	'
Available-for-sale Securities, Debt Securities, Current	148,994	'	'	'
Cash and Cash Equivalents, at Carrying Value, Total	0	'	'	'
Marketable Securities	148,994	'	'	'
Equity Securities [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cost	241,065	'	'	'
Gross Unrealized Gain	32,122	'	'	'
Gross Unrealized Loss	0	'	'	'
Available-for-sale Securities, Debt Securities, Current	273,187	'	'	'
Cash and Cash Equivalents, at Carrying Value, Total	0	'	'	'
Marketable Securities	273,187	'	'	'
Demand Deposits [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cost	3,856,285	6,831,478	'	'
Gross Unrealized Gain	0	0	'	'
Gross Unrealized Loss	0	0	'	'
Available-for-sale Securities, Debt Securities, Current	3,856,285	6,831,478	'	'
Cash and Cash Equivalents, at Carrying Value, Total	3,856,285	6,831,478	'	'
Marketable Securities	0	'	'	'
Money Market Funds [Member]	'	'	'	'
Cash and Cash Equivalents [Line Items]	'	'	'	'
Cost	93,840	'	'	'
Gross Unrealized Gain	0	'	'	'
Gross Unrealized Loss	0	'	'	'
Available-for-sale Securities, Debt Securities, Current	93,840	'	'	'
Cash and Cash Equivalents, at Carrying Value, Total	93,840	'	'	'
Marketable Securities	$0	'	'	'

Medical_Payables_Detail

Medical Payables (Detail) (USD $)	6 Months Ended
	Sep. 30, 2014
IBNR [Member]	'
Medical Payables [Line Items]	'
Balance, beginning of the period	$274,000
Incurred health care costs:	'
Current year	1,566,856
Prior years	0
Total incurred health care costs	1,566,856
Acquired medical liabilities (see Note 3 )	292,309
Claims paid:	'
Current year	-997,390
Prior years	-64,482
Total claims paid	-1,061,872
Adjustments	-197,938
Balance, end of period	873,355
Accrual Risk-pool Liability [Member]	'
Medical Payables [Line Items]	'
Balance, beginning of the period	278,561
Incurred health care costs:	'
Acquired medical liabilities (see Note 3 )	128,848
Claims paid:	'
Accrual for net deficit from full risk capitation contracts	361,733
Balance, end of period	$769,142

Carrying_Amounts_and_Fair_Valu

Carrying Amounts and Fair Values of Company's Financial Instruments (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Assets	'	'
Assets, Fair Value Disclosure	$516,021	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	3,435,086	2,354,624
Fair Value, Inputs, Level 1	'	'
Assets	'	'
Assets, Fair Value Disclosure	273,187	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2	'	'
Assets	'	'
Assets, Fair Value Disclosure	242,834	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3	'	'
Assets	'	'
Assets, Fair Value Disclosure	0	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	3,435,086	2,354,624
Money Market Funds	'	'
Assets	'	'
Assets, Fair Value Disclosure	93,840	'
Money Market Funds | Fair Value, Inputs, Level 1	'	'
Assets	'	'
Assets, Fair Value Disclosure	0	'
Money Market Funds | Fair Value, Inputs, Level 2	'	'
Assets	'	'
Assets, Fair Value Disclosure	93,840	'
Money Market Funds | Fair Value, Inputs, Level 3	'	'
Assets	'	'
Assets, Fair Value Disclosure	0	'
Equity Securities	'	'
Assets	'	'
Assets, Fair Value Disclosure	273,187	'
Equity Securities | Fair Value, Inputs, Level 1	'	'
Assets	'	'
Assets, Fair Value Disclosure	273,187	'
Equity Securities | Fair Value, Inputs, Level 2	'	'
Assets	'	'
Assets, Fair Value Disclosure	0	'
Equity Securities | Fair Value, Inputs, Level 3	'	'
Assets	'	'
Assets, Fair Value Disclosure	0	'
Warranty Liability	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	2,750,480	2,354,624
Warranty Liability | Fair Value, Inputs, Level 1	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	0	0
Warranty Liability | Fair Value, Inputs, Level 2	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	0	0
Warranty Liability | Fair Value, Inputs, Level 3	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	2,750,480	2,354,624
Holdback consideration	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	136,822	'
Holdback consideration | Fair Value, Inputs, Level 1	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	0	'
Holdback consideration | Fair Value, Inputs, Level 2	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	0	'
Holdback consideration | Fair Value, Inputs, Level 3	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	136,822	'
Mutual Funds	'	'
Assets	'	'
Assets, Fair Value Disclosure	148,994	'
Mutual Funds | Fair Value, Inputs, Level 1	'	'
Assets	'	'
Assets, Fair Value Disclosure	0	'
Mutual Funds | Fair Value, Inputs, Level 2	'	'
Assets	'	'
Assets, Fair Value Disclosure	148,994	'
Mutual Funds | Fair Value, Inputs, Level 3	'	'
Assets	'	'
Assets, Fair Value Disclosure	0	'
Conversion Feature Liability	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	547,784	'
Conversion Feature Liability | Fair Value, Inputs, Level 1	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	0	'
Conversion Feature Liability | Fair Value, Inputs, Level 2	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	0	'
Conversion Feature Liability | Fair Value, Inputs, Level 3	'	'
Liabilities	'	'
Financial Liabilities Fair Value Disclosure	$547,784	'

Summary_of_Activity_of_Level_3

Summary of Activity of Level 3 Inputs Measured on Recurring Basis (Detail) (USD $)	6 Months Ended		3 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014
			Fair Value, Inputs, Level 3	Fair Value, Inputs, Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'	'	'
Beginning Balance	'	'	$2,521,451	$2,354,624
Warrant liability incurred (Note 7)	487,620	13,316	487,620	487,620
Change in warrant liability	'	'	-121,769	-91,764
Holdback consideration	'	'	0	136,822
Conversion feature liability incurred (Note 7)	578,155	125,000	578,155	578,155
Change in conversion feature liability	'	'	-30,371	-30,371
Ending Balance	'	'	$3,435,086	$3,435,086

Computation_of_Diluted_Earning

Computation of Diluted Earnings Per Share (Detail)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	799,523	6,476,282	5,901,843	6,868,241
9% Convertible Debt	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	799,523	674,528	748,824	785,714
Warrants	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,428,067	1,495,803	1,535,402
Options	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	4,373,687	3,657,216	4,547,125

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended	6 Months Ended	1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jul. 22, 2014	Sep. 30, 2014	Sep. 30, 2014	31-May-14	Sep. 30, 2014	Sep. 30, 2014
					SCHC	SCHC	SCHC	AKM Medical Group, Inc	AKM Medical Group, Inc	AKM Medical Group, Inc
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'
Business Combination, Consideration Transferred	'	'	'	'	'	'	$2,560,391	$280,000	'	$276,822
Payments to Acquire Businesses, Gross	'	'	'	'	'	'	2,428,391	140,000	'	140,000
Business Combination, Consideration Transferred, Liabilities Incurred	'	'	'	'	'	'	132,000	136,822	'	136,822
Revenues, Total	11,665,294	2,521,421	15,759,780	5,136,115	'	'	'	'	'	1,872,529
Other Income	'	'	'	'	'	'	'	'	'	-260,624
Acquisiton Of Common Stock And Warrants Description	'	'	'The purchase price for the shares was (i) $2,000,000 in cash, (ii) $428,391 to pay off and discharge certain indebtedness of SCHC (iii) warrants to purchase up to 1,000,000 shares of the Companys common stock at an exercise price of $1.00 per share and (iv) a contingent amount of up to $1,000,000 payable, if at all, in cash.	'	'	'	'	'	'	'
Costs and Expenses, Related Party	'	'	'	'	'	'	'	'	0	37,000
Fair Value Assumptions, Exercise Price	'	'	'	'	$1	'	'	'	'	'
Fair Value Assumptions, Expected Term	'	'	'	'	'4 years	'	'	'	'	'
Fair Value Assumptions, Expected Volatility Rate	'	'	'	'	54.00%	'	'	'	'	'
Fair Value Assumptions, Risk Free Interest Rate	'	'	'	'	1.35%	'	'	'	'	'
Business Combination, Contingent Consideration, Liability	'	'	'	'	1,000,000	'	'	'	'	'
Allocated Share-based Compensation Expense, Total	856,519	568,708	975,658	2,121,012	827,000	'	'	'	'	'
Royalty Rate	'	'	'	'	1.00%	'	'	'	'	'
Business Acquisition, Share Price	'	'	'	'	$0.54	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'5 years	'	'	'	'	'
General and Administrative Expense, Total	3,451,907	1,043,565	5,461,239	2,965,395	'	124,000	124,000	'	'	'
Business Acquisitions Target Amount	$461,104	'	$461,104	'	'	'	'	'	'	'

Fair_Value_of_Consideration_Tr

Fair Value of Consideration Transferred (Detail) (USD $)	1 Months Ended	6 Months Ended
	31-May-14	Sep. 30, 2014
AKM Medical Group, Inc [Member]	'	'
Business Acquisition [Line Items]	'	'
Cash consideration	$140,000	$140,000
Fair value of warrant consideration	136,822	136,822
Total purchase consideration	280,000	276,822
Southern California Heart Centers [Member]	'	'
Business Acquisition [Line Items]	'	'
Cash consideration	'	2,428,391
Fair value of warrant consideration	'	132,000
Total purchase consideration	'	$2,560,391

Allocation_of_Total_Purchase_P

Allocation of Total Purchase Price (Detail) (USD $)	Sep. 30, 2014	30-May-14
Business Acquisition [Line Items]	'	'
Cash and cash equivalents	'	$356,359
Marketable securities	'	389,094
Accounts receivable	'	27,217
Prepaid expenses and other current assets	'	26,311
Identifiable intangible assets	1,121,000	156,000
Goodwill	'	-216,563
Accounts payable and accrued liabilities	'	-40,439
Medical payables	'	-421,157
Net assets acquired	'	276,822
SCHC	'	'
Business Acquisition [Line Items]	'	'
Cash and cash equivalents	264,601	'
Accounts receivable	840,433	'
Prepaid expenses and other current assets	82,430	'
Identifiable intangible assets	1,121,000	'
Goodwill	161,559	'
Accounts payable and accrued liabilities	134,427	'
Receivable from affiliate	67,714	'
Net assets acquired	2,560,391	'
Property and equipment	584,377	'
Other assets	66,762	'
Total assets acquired	3,188,876	'
Note payable to financial institution	463,582	'
Deferred tax liability	30,477	'
Total liabilities assumed	$628,485	'

Intangible_Assets_Acquired_Det

Intangible Assets Acquired (Detail) (USD $)	Sep. 30, 2014	30-May-14	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Network Relationships	Trade Names	Noncompete Agreements
Business Acquisition [Line Items]	'	'	'	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$1,121,000	$156,000	$910,000	$110,000	$101,000
Finite-Lived Intangible Asset, Useful Life	'	'	'5 years	'5 years	'3 years

Pro_Forma_Results_Of_Medical_C

Pro Forma Results Of Medical Clinic Acquisition (Detail) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Business Acquisition [Line Items]	'	'	'	'
Net revenue	$11,899,142	$4,477,640	$17,956,326	$9,135,956
Net income (loss)	$1,410,936	($1,067,658)	($209,441)	($3,054,008)
Basic income (loss) per share	$0.03	($0.02)	$0	($0.08)
Diluted income (loss) per share	$0.03	($0.02)	$0	($0.08)

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Amortization of Intangible Assets	$125,000	$1,000	$130,000	$1,000

Summary_of_Goodwill_Activity_D

Summary of Goodwill Activity (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2014
			AKM Medical Group, Inc [Member]	Southern California Heart Centers [Member]
Goodwill [Line Items]	'	'	'	'
Balance, beginning of period	$439,694	$494,700	'	'
Acquisition	'	'	-216,565	161,559
Balance, end of period	$439,694	$494,700	'	'

Other_Intangible_Assets_Detail

Other Intangible Assets (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Exclusivity	Non-compete	Payor relationships	Network relationships	Trade name
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'
Weighted-average life (Yrs)	'	'	'4 years	'4 years	'5 years	'5 years	'5 years
Intangible assets, Beginning Balance	$1,345,400	$68,400	$40,000	$28,400	$0	$0	$0
Intangible assets, Addition	1,277,000	'	0	120,000	94,000	910,000	153,000
Intangible assets, Ending Balance	1,345,400	68,400	40,000	148,400	94,000	910,000	153,000
Accumulated amortization, Beginning Balance	-139,081	-8,773	'	'	'	'	'
Accumulated amortization, Addition	-130,308	'	'	'	'	'	'
Accumulated amortization, Ending Balance	-139,081	-8,773	'	'	'	'	'
Total other intangibles, net, Beginning Balance	1,206,319	59,627	'	'	'	'	'
Total other intangibles, net, Addition	1,146,692	'	'	'	'	'	'
Total other intangibles, net, Ending Balance	$1,206,319	$59,627	'	'	'	'	'

Future_Amortization_Expense_De

Future Amortization Expense (Detail) (USD $)	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]	'
October 1, 2014 to March 31, 2015	$255,000
2016	326,000
2017	259,000
2018	192,000
2019	125,000
Thereafter	$46,000

Accounts_Payable_and_Accrued_L2

Accounts Payable and Accrued Liabilities (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Account Payable And Accrued Liabilities [Line Items]	'	'
Accounts payable	$1,456,796	$824,334
Physician share of MSSP ACO savings	1,400,000	0
Accrued compensation	809,772	546,078
Income taxes payable	85,477	4,149
Accrued interest	28,049	19,780
Accrued professional fees	12,550	52,699
Accounts payable and accrued liabilities	$3,792,645	$1,447,040

Notes_and_Lines_of_Credit_Paya2

Notes and Lines of Credit Payable - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

6 Months Ended

Jul. 31, 2014

Jul. 31, 2014

Mar. 28, 2014

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Sep. 30, 2014

Mar. 28, 2014

Sep. 30, 2014

Jan. 06, 2014

Dec. 07, 2013

Sep. 01, 2013

Sep. 30, 2014

Dec. 20, 2013

Dec. 20, 2013

Sep. 30, 2014

Oct. 15, 2013

Sep. 30, 2014

Mar. 28, 2014

Dec. 20, 2013

Sep. 30, 2014

Sep. 30, 2014

Mar. 28, 2014

Sep. 30, 2014

Mar. 28, 2014

2014 NNA Financing

2014 NNA Financing

NNA

Medical Clinic Acquisition Promissory Notes

Medical Clinic Acquisition Promissory Notes

Medical Clinic Acquisition Promissory Notes

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Secured Revolving Credit Facility

Secured Revolving Credit Facility

Convertible Notes Payable

Convertible Notes Payable

Senior secured note

Senior secured note

Term Loan

Term Loan

Revolving Loan [Member]

Revolving Loan [Member]

Maximum

Minimum

2014 NNA Financing

Amended

Amended

2014 NNA Financing

2014 NNA Financing

SpaGus

SpaGus

Senior Secured Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt, interest rate

8.00%

8.00%

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

8.00%

'

'

8.00%

'

'

'

'

Debt, maturity date

'

'

'

'

'

'

'

'

'

'

'

'

28-Mar-19

'

'

'

'

'

'

'

'

'

'

'

'

Revolving line of credit carrying amount

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

$2,000,000

'

'

'

'

'

'

'

'

Line of credit facility amount outstanding

'

'

'

'

'

'

'

'

'

'

'

'

94,764

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, interest rate description

'

'

'

'

'

'

'

'

'

'

'

'

'prime rate (as defined) plus 4.50%

'

'

'(i) three month LIBOR and (ii) 6.0 %

'

'

'

'

'

'

'

'three month LIBOR plus 6.0%

'

Line of credit facility, frequency of payment and payment terms

'

'

'

'

'

'

'

'

'

'

'

'

'interest only is payable monthly, and matures June 5, 2015

'

'

'

'

'

'

'

'

'

'

'

'

Senior notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

Debt Instrument, Payment Terms

'

'

'

'

'

'

'

'

'

'five

'eight

'ten

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition Fair Value Of Note Interest Rate

'

'

'

'

'

'

'

'

'

5.30%

5.46%

5.45%

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility, maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

2,000,000

'

'

'

'

'

'

'

'

'

'

Proceeds from repayment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

Proceeds from Issuance of Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

230,000

'

'

'

'

Secured debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000,000

'

'

Secured line of credit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

Convertible debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

Class of warrant or right, number of securities called by warrants or rights

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of first year term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87,500

'

'

'

Repayment of second year term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

122,500

'

'

'

Repayment of third year term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

122,500

'

'

'

Repayment of fourth year term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

175,000

'

'

'

Repayment of fifth year term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

210,000

'

'

'

Term Loan accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

1,183,856

'

1,305,435

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,305,435

'

'

'

Debt Instrument, Fee Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,000

'

'

'

Amortization Of Debt Discount Premium

'

'

'

177,963

116,248

'

20,930

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Party Costs

'

'

'

235,119

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Finance Costs Net

'

'

'

'

'

'

150,101

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment

'

'

'

'

'

'

'

'

'

15,000

10,000

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance Of Debt Instruments On Fair Value

'

'

'

'

'

'

9,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

2.10%

1.63%

2.31%

'

'

'

2.31%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

71.80%

63.70%

71.40%

'

'

'

71.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price

'

'

'

'

'

'

$0.45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

'

0.00%

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Value For Financing

'

'

'

'

'

'

899,739

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount On Shares Issuance

'

'

'

'

'

'

1,100,261

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount On Term Loan

'

'

'

'

'

'

1,254,363

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Warrant Liabilities

'

'

'

'

'

'

2,354,624

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term

'6 years 8 months 12 days

'6 years

'7 years

'

'

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization Of Debt Discount

'

'

'

'

'

'

51,072

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization Of Debt Discount Premium Related To Equity

'

'

'

'

'

'

7,998

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term Loan Value Under Agreement

'

'

'

'

'

'

$5,745,637

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes_and_Lines_of_Credit_Paya3

Notes and Lines of Credit Payable (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Senior Secured Note [Line Items]	'	'
Notes and Loans Payable	$5,648,408	$5,789,329
Revolving Credit Facility [Member]	'	'
Senior Secured Note [Line Items]	'	'
Notes and Loans Payable	94,764	94,764
Loans Payable [Member]	'	'
Senior Secured Note [Line Items]	'	'
Notes and Loans Payable	$5,553,644	$5,694,565

Notes_and_Lines_of_Credit_Paya4

Notes and Lines of Credit Payable (Parenthetical) (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Debt Instrument [Line Items]	'	'
Debt discount	$1,183,856	$1,305,435

Interest_Expense_Associated_wi

Interest Expense Associated with Notes Payable (Detail) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Associated of Interest Expense [Line Items]	'	'	'	'
Interest expense	$329,258	$200,562	$606,125	$362,252
Notes Payable	'	'	'	'
Associated of Interest Expense [Line Items]	'	'	'	'
Interest expense	143,845	25,089	287,998	56,087
Amortization of loan fees and discount	71,673	35,061	142,924	39,780
Interest expense, debt	$215,518	$60,151	$430,922	$95,868

Convertible_Notes_Payable_Addi

Convertible Notes Payable - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Jul. 31, 2014

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Feb. 21, 2013

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Mar. 31, 2014

Oct. 16, 2009

Jul. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

Jul. 31, 2014

8% Senior Subordinated Convertible Notes due February 1, 2015

8% Senior Subordinated Convertible Notes due February 1, 2015

8% Senior Subordinated Convertible Notes due February 1, 2015

9% Senior Subordinated Convertible Notes due February 15, 2016

9% Senior Subordinated Convertible Notes due February 15, 2016

10% Senior Subordinated Callable Convertible Notes

NNA Financing 8 Convertible Note [Member]

NNA Financing 8 Convertible Note [Member]

NNA 8 Convertible Notes [Member]

NNA 8 Convertible Notes [Member]

NNA 8 Convertible Notes [Member]

NNA 8 Convertible Notes [Member]

Common Stock [Member]

Warrant

Debt conversion description [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes payable, interest payment terms

'

'

'

'

'

'

'

'If the Average Daily Value of Trades (ADVT) during the prior 90 days as reported by Bloomberg is greater than $100,000, the Note is callable at a price of 105% of the Notes par value, and if the ADVT is less than $100,000, the 9% Notes are callable at a price of 110% of the Notes par value.

'

'

'

'

'

'

'

'

Debt conversion, price per share of common stock

'

$1

'

'

'

'

'

$0.40

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

660,000

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

$0.45

'

'

'

'

'

'

'

$1

Gross Proceeds From Issuance Of Debt

'

'

'

'

'

'

'

'

'

$1,250,000

'

'

'

'

'

'

Payments of Debt Issuance Costs

'

20,000

0

'

'

'

'

'

'

25,000

'

'

'

'

'

'

Convertible Notes Payable

'

1,953,587

'

962,978

150,000

953,189

0

1,000,398

962,978

'

'

'

'

'

'

'

Debt Instrument Total Cash Payment

'

'

'

'

106,000

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Total Shares Issuance

'

'

'

'

182,000

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

Debt Instrument, Unused Borrowing Capacity, Amount

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

Proceeds from Issuance of Debt

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

1,183,856

'

1,305,435

'

1,046,811

'

99,973

137,393

'

1,065,775

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

8.00%

'

'

'

'

8.00%

'

9.00%

'

'

8.00%

'

'

'

'

'

Debt Instrument Stock Initial Price

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

578,155

125,000

'

'

'

'

'

'

'

578,155

'

'

'

'

'

Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'

'

'4 years 8 months 12 days

'

'6 years 8 months 12 days

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

1.60%

'

2.10%

'

'

'

Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

'

'

'

'

'

71.80%

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

54.80%

'

0.49%

'

'

'

Share Price

$0.49

'

'

'

'

'

'

'

'

'

$0.49

'

'

$0.45

'

'

Percentage For Down round financing

100.00%

'

'

'

'

'

'

'

'

'

100.00%

'

'

100.00%

100.00%

'

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

Fair Value Of Warrant Liabilities

'

'

'

'

'

'

'

'

'

'

'

'

487,620

'

'

'

Stock Issued

'

'

'

'

'

'

'

'

'

'

'

'

$1,000,000

'

'

'

LongTerm_Debt_Detail

Long-Term Debt (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Feb. 21, 2013
Debt Instrument [Line Items]	'	'	'
Convertible Notes Payable	$1,953,587	$962,978	'
9% Senior Subordinated Convertible Notes due February 15, 2016	'	'	'
Debt Instrument [Line Items]	'	'	'
Convertible Notes Payable	1,000,398	962,978	'
8% Senior Subordinated Convertible Notes due	'	'	'
Debt Instrument [Line Items]	'	'	'
Convertible Notes Payable	$953,189	$0	$150,000

Convertible_Notes_Parenthetica

Convertible Notes (Parenthetical) (Detail) (USD $)	Sep. 30, 2014	Jul. 31, 2014	Mar. 31, 2014	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014
				9% Senior Subordinated Convertible Notes due February 15, 2016	9% Senior Subordinated Convertible Notes due February 15, 2016	8% Senior Subordinated Convertible Notes due February 1, 2015
Debt Instrument [Line Items]	'	'	'	'	'	'
Debt, interest rate	'	8.00%	'	9.00%	'	8.00%
Debt discount	$1,183,856	'	$1,305,435	$99,973	$137,393	$1,046,811
Debt instrument, maturity date	'	'	'	15-Feb-16	'	'

Interest_Expense_on_Convertibl

Interest Expense on Convertible Notes (Detail) (USD $)	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
					Convertible Notes Payable	Convertible Notes Payable	Convertible Notes Payable	Convertible Notes Payable
Schedule Of Debt Instrument Interest Expense [Line Items]	'	'	'	'	'	'	'	'
Interest expense	$329,258	$200,562	$606,125	$362,252	$52,856	$111,387	$77,881	$185,619
Amortization of loan fees and discount	'	'	'	'	60,884	29,025	97,322	80,766
Interest expense, debt	'	'	'	'	$113,740	$140,411	$175,203	$266,384

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Jul. 31, 2014

Jul. 31, 2014

Mar. 28, 2014

Sep. 30, 2014

Mar. 31, 2014

Mar. 28, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 28, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jul. 31, 2014

Sep. 30, 2014

Oct. 18, 2012

Sep. 30, 2014

Apr. 29, 2013

NNA of Nevada, Inc

Monte Carlo method

Equity and Debt Financing

Equity and Debt Financing

Note warrant

Placement agent warrants

Maximum

Maximum

9% Notes Payable

Restricted Stock

2010 Equity Incentive Plan

2012 Equity Incentive Plan

2013 Equity Incentive Plan

2013 Equity Incentive Plan

NNA of Nevada, Inc

Equity and Debt Financing

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity incentive plan, shares authorized for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

Equity incentive plan, additional shares authorized for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,000,000

'

'

Equity incentive plan, shares available for future grant

'

'

'

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

1,900,000

'

Issuance of common stock for services (shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000,000

'

'

'

Common Stock, shares authorized

'

'

'

100,000,000

100,000,000

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

Convertible notes, interest rate

8.00%

8.00%

'

'

'

'

'

'

'

'

'

'

'

9.00%

'

'

'

'

'

Restricted shares granted to agent

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

Share price

$0.49

$0.49

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

Exercise price

'

'

'

'

'

'

'

'

$0.45

'

'

'

'

'

'

'

'

'

'

Expected term

'6 years 8 months 12 days

'6 years

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility rate

71.80%

63.70%

71.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate

2.10%

1.63%

2.31%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend rate

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

1,000,000

2,000,000

2,000,000

'

1,000,000

'

'

'

'

'

'

Class Of Warrant Or Right Price Per Share

'

'

$0.45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding

'

'

'

'

'

'

'

'

$900,000

'

'

'

'

'

'

'

'

'

'

Price Per Share Level For Future Issuance Of Common Shares

'

'

'

'

'

'

$0.90

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

$1

$1

$1

$2

'

'

'

'

'

'

'

'

Equity and debt investment

'

'

'

'

'

$12

'

'

$12,000,000

'

'

'

'

'

'

'

'

'

'

Percentage For Down Round Finance

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage For Liquidated Damages Equal Of Purchase Price

'

'

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

'

'

'

0

'

'

'

'

'

'

'

'

'

'

565,000

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

'

$0.24

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

'6 years 8 months 12 days

'6 years

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

2.10%

1.63%

2.31%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

71.80%

63.70%

71.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Companys_Restricted

Summary of Company's Restricted Stock (Detail) (USD $)	1 Months Ended	6 Months Ended	12 Months Ended
	Jul. 31, 2014	Sep. 30, 2014	Mar. 31, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]	'	'	'
Unvested or unlapsed shares, Shares	'	907,407	'
Granted, Shares	'	0	'
Vested / lapsed, Shares	'	-611,111	'
Forfeited, Shares	'	0	'
Unvested or unlapsed shares, Shares	'	296,296	907,407
Unvested or unlapsed shares, Average Life (In Years)	'	'1 year 1 month 6 days	'1 year 3 months 18 days
Granted, Average Life (In Years)	'	'0 years	'
Vested / lapsed, Average Life (In Years)	'	'0 years	'
Forfeited, Average Life (In Years)	'	'0 years	'
Unvested or unlapsed shares, Average Intrinsic Value	'	$0	'
Granted, Average Intrinsic Value	'	$0	'
Vetsed / lapsed, Average Intrinsic Value	'	$0	'
Forfeited, Average Intrinsic Value	'	$0	'
Unvested or unlapsed shares, Average Intrinsic Value	'	$0.06	$0
Unvested or unlapsed shares, Fair Value	'	$0.41	'
Granted, Fair Value	'	$0	'
Vested / lapsed, Fair Value	$0.24	$0	'
Forfeited, Fair Value	'	$0	'
Unvested or unlapsed shares, Fair Value	'	$0.41	$0.41

Stock_Option_Activity_Detail

Stock Option Activity (Detail) (USD $)	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Shares	'	'
Beginning balance	6,287,000	'
Granted	565,000	'
Cancelled	-100,000	'
Exercised	0	'
Expired	0	'
Forfeited	0	'
Ending balance	6,752,000	6,287,000
Vested and exercisable	6,145,889	'
Weighted Average Per Share Exercise Price	'	'
Beginning balance	$0.20	'
Granted	$1	'
Cancelled	$0	'
Exercised	$0	'
Expired	$0	'
Forfeited	$0	'
Ending balance	$0.22	$0.20
Vested and exercisable	$0.21	'
Weighted Average Remaining Life (Years)	'	'
Balance	'8 years 2 months 12 days	'8 years 8 months 12 days
Granted	'0 years	'
Cancelled	'0 years	'
Exercised	'0 years	'
Expired	'0 years	'
Forfeited	'0 years	'
Vested and exercisable	'7 years 6 months	'
Weighted Average Per Share Intrinsic Value	'	'
Beginning Balance	$0.11	'
Granted	$0	'
Cancelled	$0	'
Exercised	$0	'
Expired	$0	'
Forfeited	$0	'
Ending balance	$0.24	$0.11
Vested and exercisable	$0.26	'

Summary_of_Restricted_Stock_Aw

Summary of Restricted Stock Award (Detail) (USD $)	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Schedule Of Share Based Compensation Restricted Stock Units Award Activity [Line Items]	'	'
Shares,Balance, Beginning	3,752,000	'
Shares,Granted	112,000	'
Shares,Released	-183,996	'
Shares,Balance, Ending	3,680,004	3,752,000
Vested and exercisable	2,461,694	'
Balance, Weighted Average Remaining Vesting Life (Years)	'7 months 6 days	'9 months 18 days
Balance, Weighted Average Remaining Vesting Life, Granted	'0 years	'
Balance, Weighted Average Remaining Vesting Life, Released	'0 years	'
Weighted Average Per Share Intrinsic Value, Balance, Beginning	$0.02	'
Weighted Average Per Share Intrinsic Value, Granted	0	'
Weighted Average Per Share Intrinsic Value, Released	0	'
Weighted Average Per Share Intrinsic Value, Balance, Ending	$0.73	$0.02
Weighted Average Per Share Fair Value, Balance, Beginning	$0.03	'
Weighted Average Per Share Fair Value, Granted	$0.78	'
Weighted Average Per Share Fair Value, Released	$0	'
Weighted Average Per Share Fair Value, Balance, Ending	$0.05	$0.03

Total_Unrecognized_Compensatio

Total Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements (Detail) (USD $)	Sep. 30, 2014
Common stock options	'
Employee Service Share -Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized [Line Items]	'
Unrecognized compensation cost	$198,195
Restricted stock	'
Employee Service Share -Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized [Line Items]	'
Unrecognized compensation cost	139,400
ACO Plan restricted stock	'
Employee Service Share -Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized [Line Items]	'
Unrecognized compensation cost	$57,179

Summary_of_StockBased_Compensa

Summary of Stock-Based Compensation Expense Related to Common Stock and Common Stock Option Awards (Detail) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Summary Of Stock Based Compensation Expense Related To Common Stock and Common Stock Option Awards [Line Items]	'	'	'	'
Stock-based compensation expense	$856,519	$568,708	$975,658	$2,121,012
Cost of services	'	'	'	'
Summary Of Stock Based Compensation Expense Related To Common Stock and Common Stock Option Awards [Line Items]	'	'	'	'
Stock-based compensation expense	-17,822	86,630	10,921	575,509
General and administrative	'	'	'	'
Summary Of Stock Based Compensation Expense Related To Common Stock and Common Stock Option Awards [Line Items]	'	'	'	'
Stock-based compensation expense	$874,341	$482,078	$964,737	$1,545,503

Warrants_Outstanding_Detail

Warrants Outstanding (Detail) (USD $)	6 Months Ended
	Sep. 30, 2014
Class of Warrant or Right [Line Items]	'
Weighted Average Per Share Intrinsic Value, Outstanding	$0.02
Weighted Average Per Share Intrinsic Value, Granted	0
Weighted Average Per Share Intrinsic Value, Exercised	0
Weighted Average Per Share Intrinsic Value, Cancelled	0
Weighted Average Per Share Intrinsic Value, Outstanding	$0
Number Of warrants, Outstanding	7,145,000
Number Of warrants, Granted	2,000,000
Number Of warrants, Exercised	0
Number Of warrants, Cancelled	0
Number Of warrants, Outstanding	9,145,000

Warrants_Detail

Warrants (Detail) (USD $)	6 Months Ended
	Sep. 30, 2014
Class of Warrant or Right [Line Items]	'
Warrants outstanding	9,145,000
Weighted average remaining contractual life	'4 years 9 months 18 days
Warrants exercisable	9,145,000
Weighted average exercise price per share	$0.97
Warrant Exercise Price Range One 0.11485	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$0.11
Warrants outstanding	1,250,000
Weighted average remaining contractual life	'1 year 9 months 18 days
Warrants exercisable	1,250,000
Weighted average exercise price per share	$0.11
Warrant Exercise Price Range Two 0.11485	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$0.11
Warrants outstanding	250,000
Weighted average remaining contractual life	'1 year 9 months 18 days
Warrants exercisable	250,000
Weighted average exercise price per share	$0.11
Warrant Exercise Price Range Three 0.45000	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$0.45
Warrants outstanding	500,000
Weighted average remaining contractual life	'1 year 9 months 18 days
Warrants exercisable	500,000
Weighted average exercise price per share	$0.45
Warrant Exercise Price Range Four 0.50000	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$0.50
Warrants outstanding	100,000
Weighted average remaining contractual life	'3 years 1 month 6 days
Warrants exercisable	100,000
Weighted average exercise price per share	$0.50
Warrant Exercise Price Range Five 0.45000	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$0.45
Warrants outstanding	825,000
Weighted average remaining contractual life	'3 years 3 months 18 days
Warrants exercisable	825,000
Weighted average exercise price per share	$0.45
Warrant Exercise Price Range Six 0.40000	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$0.40
Warrants outstanding	220,000
Weighted average remaining contractual life	'3 years 3 months 18 days
Warrants exercisable	220,000
Weighted average exercise price per share	$0.40
Warrant Exercise Price Range Seven 1.00000	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$1
Warrants outstanding	2,000,000
Weighted average remaining contractual life	'6 years 6 months
Warrants exercisable	2,000,000
Weighted average exercise price per share	$1
Warrant Exercise Price Range Eight 2.00000	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$2
Warrants outstanding	2,000,000
Weighted average remaining contractual life	'6 years 6 months
Warrants exercisable	2,000,000
Weighted average exercise price per share	$1
Warrant Exercise Price Range Nine 1.00000	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$1
Warrants outstanding	1,000,000
Weighted average remaining contractual life	'6 years 6 months
Warrants exercisable	1,000,000
Weighted average exercise price per share	$1
Warrant Exercise Price Range Ten 1.00000	'
Class of Warrant or Right [Line Items]	'
Exercise Price Per Share	$1
Warrants outstanding	1,000,000
Weighted average remaining contractual life	'3 years 9 months 18 days
Warrants exercisable	1,000,000
Weighted average exercise price per share	$1

Amount_of_Shares_of_Common_Sto

Amount of Shares of Common Stock Reserved (Detail)	Sep. 30, 2014	Mar. 31, 2014
Stock Option Outstanding [Line Items]	'	'
Common stock issued and outstanding	49,134,549	'
Conversion of 9% Notes	2,750,000	'
Conversion of 8% Notes	2,000,000	'
Warrants outstanding	9,145,000	7,145,000
Stock options outstanding	6,752,000	6,287,000
Remaining shares issuable under 2013 Equity Incentive Plan	1,900,000	'
Common stock reserved for future issuance	71,681,549	'

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	1 Months Ended				1 Months Ended
	Oct. 27, 2014	Oct. 27, 2014	Oct. 14, 2014	Oct. 23, 2014	Oct. 23, 2014	Oct. 27, 2014	Oct. 27, 2014
		Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event
					Common Stock	BCHC Agreement	HCHHA Agreement
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Business Acquisition Contingent Consideration Cash Payment	'	'	'	10,000	'	'	'
Description for Purchase Agreement Interest	'51% of the membership interests	'	'	'	'	'	'
Cash Received Monthly	'	$15,000	'	'	'	'	'
Business Acquisition Working Capital	'	'	'	'	'	145,000	50,000
Business Acquisition Contingent Payment	'	'	'	'	'	400,000	150,000
Business Acquisition Installments Payment	'	'	'	'	'	100,000	75,000
Stock Issued During Period, Shares, Other	'	'	'	'	500,000	'	'
Capital	'	613,889	'	'	'	'	'
Business Acquisition, Transaction Costs	'	'	'	'	'	900,000	300,000
Maximum Allowance For New Premises Improved Provided By Landlord	'	'	659,360	'	'	'	'
Operating Leases, Rent Expense	'	'	37,913.20	'	'	'	'
Annual Increases In Base Rent Each Year	'	'	43,957.33	'	'	'	'
Maximum Amount of Increase In Lease Rent Subject To Other Terms of Lease	'	'	$228,049.27	'	'	'	'